



AZERBAIJAN • KAZAKHSTAN • KYRGYZSTAN • TAJIKISTAN • TURKMENISTAN • UZBEKISTAN

Accessibility of HIV Prevention, Treatment and Care Services for People who Use Drugs and Incarcerated People in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan

Legislative and Policy Analysis and Recommendations for Reform



UNODC

United Nations Office on Drugs and Crime



Title: Accessibility of HIV Prevention, Treatment and Care Services for People who Use Drugs and Incarcerated People in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan: Legislative and Policy Analysis and Recommendations for Reform

Abstract

This report analyses national programmes on HIV and drug control, administrative and criminal laws, and relevant governmental decrees and ministerial orders which were in effect in 2007-2009 in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan. Results of the analysis indicate that in the absence of regulatory frameworks that clearly enable and support evidence-based HIV prevention and treatment interventions, including harm reduction services, national laws, policies and programmes may and do hinder the full implementation of effective approaches to preventing and treating HIV infection among vulnerable groups such as prisoners and people who use drugs. These laws, policies and programmes embody: predominantly punitive drug control practices; limitations of the rights of people living with HIV, people who use drugs, and prisoners with HIV and/or drug dependence; broad provisions for non-voluntary medical interventions such as coercive drug testing, compulsory treatment of drug dependence, and mandatory HIV testing; and limited meaningful participation of civil society, including groups of people living with HIV, people who use drugs and prisoners, in the development, implementation and evaluation of the effectiveness of national strategies and laws both on HIV and on drugs. This report presents recommendations to governments for legislative and policy reform aimed at strengthening the national response to the HIV epidemic and, specifically, at improving accessibility of evidence-based HIV-related services for drug users and incarcerated people. In addition, recommendations are also directed to UN and other international aid organizations for supporting countries in implementing such reforms.

Key words: 1. Human rights 2. HIV 3. Drug use 4. Prisons 5. Legislative review 6. Law reform 7. Central Asia 8. Azerbaijan

© United Nations Office on Drugs and Crime, Regional Office for Central Asia
© Canadian HIV/AIDS Legal Network

This publication has not been formally edited. It is not an official publication of the United Nations. The contents of this publication do not necessarily reflect the views or policies of the United Nations Office on Drugs and Crime (UNODC) or contributory organizations and neither do they imply any endorsement. The designations employed do not imply the expression of any opinion whatsoever on the part of the United Nations. The boundaries, names and designations in this book do not imply official endorsement or acceptance by the United Nations. All reasonable efforts have been made by UNODC and the Canadian HIV/AIDS Legal Network to verify the information contained in this publication and that it was accurate as of December 2009. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall UNODC or the Canadian HIV/AIDS Legal Network be liable for damages arising from its use.

First published in 2010
Printed in Ashgabat, Turkmenistan by the UNODC Regional Office for Central Asia. This publication is available on the Internet at www.unodc.org/centralasia

This publication may be freely reproduced or distributed with appropriate acknowledgment.

For further information please contact:

United Nations Office on Drugs and Crime, Regional Office for Central Asia
30a Abdulla Kahhar Street
Tashkent, 700100 Uzbekistan
Telephone: (+998-71)120-80-50
Fax: (+998-71)120-62-90

or
UNODC Programme Office in Astana
26 Bukeykhan Street, UN House,
010000, Astana, Kazakhstan
Telephone: (+7- 7172) 32 06 47
Fax: (+7- 7172) 59 25 40

TABLE OF CONTENTS

ABBREVIATIONS AND ACRONYMS.....6

ACKNOWLEDGMENTS7

EXECUTIVE SUMMARY10

I. INTEGRATED REPORT18

1. INTRODUCTION.....18

1.1 Background to the project.....18

1.2 Rationale for legislative reform and the importance of human rights-based policy.....20

1.3 Methodology.....25

2. PROJECT COUNTRIES: AN OVERVIEW.....28

2.1 Population and geography28

2.2 Drug use28

2.3 HIV epidemic29

2.5 Criminal justice systems.....32

2.6 Health care systems33

2.7 Correctional systems.....35

2.8 Human rights situation: HIV, drug use, prisons.....36

3. ADMINISTRATIVE AND CRIMINAL LAW ISSUES39

3.1 Laws related to drugs: current situation in the project countries39

3.2 Rationale for reforming drug laws40

3.3 Recommendations for reforming drug laws and policies.....43

4. HEALTH CARE SYSTEMS AND SERVICES50

4.1 Health care in the project countries50

4.2 Rationale for reforms.....73

4.3 Recommendations for policy and legislative reform in health care and social protection.....91

5. PRISONS.....101

5.1 Prison systems and populations: an overview101

5.2 HIV infection, drug use and risk behaviours in prisons: current situation.....101

5.3 Current law, policy and practice regarding HIV infection and drug use in prisons103

5.4 Rationale for penal reforms.....107

5.5 Recommendations for penal reform115

6. LEGISLATIVE DISCRIMINATION AND RESTRICTION OF RIGHTS121

6.1 Current situation in the project countries.....121

6.1.1 Discrimination against people living with HIV122

6.1.2 Discrimination against people dependent on drugs125

6.2 Rationale for legislative and policy reform to address discrimination127

6.3 Recommendations for policy and legislative reform to eliminate discrimination133

7. RECOMMENDATIONS FOR UN AND OTHER DEVELOPMENT AID.....135

II. COUNTRY REPORTS.....139

AZERBAIJAN.....141

KAZAKHSTAN179

KYRGYZSTAN223

TAJIKISTAN.....261

TURKMENISTAN295

UZBEKISTAN337

APPENDIES.....374

APPENDIX 1: Comparative tables of legal classification and threshold quantities
of controlled psychoactive substances in project countries374

APPENDIX 2: Assessment tool378

APPENDIX 3: Training Module397

APPENDIX 4: Self-assessment checklist.....416

APPENDIX 5: Glossary of terms423

ABBREVIATIONS AND ACRONYMS

AIDS	Acquired immunodeficiency syndrome
CESCR	Committee on Economic, Social and Cultural Rights
CHR	Commission on Human Rights
CIS	Commonwealth of Independent States
CND	Commission on Narcotic Drugs
EU	European Union
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria
HIV	Human immunodeficiency virus
HRW	Human Rights Watch
ICCPR	International Covenant on Civil and Political Rights
ICESCR	International Covenant on Economic, Social and Cultural Rights
IDU	injection drug use (or injecting drug user)
IHRA	International Harm Reduction Association
IHRD	International Harm Reduction Development Programme
ILO	International Labour Organization
IPU	Inter-Parliamentary Union
OHCHR	Office of the (UN) High Commissioner for Human Rights
OSI	Open Society Institute
PLHIV	People living with HIV
TB	Tuberculosis
UDHR	Universal Declaration of Human Rights
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNDCP	United Nations Drug Control Programme
UNDP	United Nations Development Programme
UNGASS	UN General Assembly Special Session
UNODC	United Nations Office on Drugs and Crime
WHO	World Health Organization

ACKNOWLEDGMENTS

This publication is the result of the collective work of a large group of dedicated people representing Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, the United Nations Office on Drugs and Crime, Regional Office for Central Asia (UNODC ROCA), and the Canadian HIV/AIDS Legal Network. Each of the persons listed below contributed to the composition of this proceeding.

Nina Kerimi, UNODC Regional Project Coordinator, formulated the goal of the legislative analysis and developed Terms of Reference for the international and national consultants, participated in drafting the programme of the initial training for national consultants and co-facilitated it; provided overall coordination and technical backstopping of the multi-country team work, including comments and substantive input to each section of the publication.

Leah Utyasheva, Senior Policy Analyst of the Canadian HIV/AIDS Legal Network, the principal international consultant commissioned by UNODC to perform this work, developed the Assessment Tool for analysis of national legislation of participating countries and its compliance with international human rights standards. She provided technical guidance to national experts throughout the assignment. Using information provided by the country teams based on the Assessment tool she supplemented it with additional research and composed first drafts of country reports and the integrated report. She composed the Training Module to be used in similar endeavours, the Self-Assessment Checklist, and the Glossary of terms. She participated in the development of the training programme, facilitated the training, and presented the findings of the legislative analyses at international conferences.

Richard Elliott, Executive Director of the Canadian HIV/AIDS Legal Network, provided significant input regarding the structure of the entire publication and its substantive content, including in the writing and editing of the English version.

Joanne Csete, previous executive director of the Canadian HIV/AIDS Legal Network, and Richard Pearshouse, Director of Research & Policy at the Canadian HIV/AIDS Legal Network contributed to the design of the methodology and structure of the assessment project. Richard Pearshouse and Mirzakhid Sultanov, UNODC Regional Advisor on HIV/AIDS, participated in the development of the training programme and co-facilitated the training for national experts. Joanne Csete and Richard Pearshouse both contributed to the editing and writing of the text.

This work could not have been accomplished without the devotion and professionalism of the following national experts who provided background information needed for the analysis, conducted the assessment of national legislation using the standard Assessment Tool, presented their findings at stakeholder meetings, and provided feedback to draft country reports composed by the UNODC international consultant:

REPUBLIC OF AZERBAIJAN:

Mr. Hadi Rejebli	Chair, Permanent Commission on Social and Political Issues, "Milli Meclis"(Parliament)
Mr. Elkhan Azizov	Lawyer, Ministry of Health
Mr. Adil Alekperov	Lawyer, Department on Special Issues, Ministry of Interior
Mr. Araz Aliguliyev	Director, NGO "Shefa"
Ms. Kamala Amirxanova	Prosecutor, Department of Law Enforcement, Office of Prosecutor General
Mr. Senan Hajiyev	Lawyer, Ministry of Justice
Mr. Jeyhun Huseynov	Consultant, Department of Military and Administrative Issues, Cabinet of Ministers
Mr. Ilgar Jafarov	Senior Consultant, Department of Administration and Military Legislation, Apparatus of Parliament

REPUBLIC OF KAZAKHSTAN:

Ms. Dinara Abdrakhmanova	Lawyer, Senior Specialist, Section for Social and Legal Protection of Inmates, Criminal and Executive System Committee, Ministry of Justice
Ms. Nuriya Gafarova	Head, Department of Management and Methodology, Republican Centre for Applied Research on Drug Addiction, Ministry of Health
Ms. Lolita Ganina	Head, Epidemiological Department, Republican AIDS Centre, Ministry of Health
Ms. Korkem Zhetpisbayeva	Senior Specialist, Department of Medical Service, Criminal and Executive System Committee, Ministry of Justice
Ms. Aigul Katrenova	Senior Specialist, Sanitary Epidemiological Surveillance Committee, Ministry of Health
Ms. Zhanar Kusbergenova	Lawyer, Senior Specialist, Department of Organizational and Legislative Support, Ministry of Health
Ms. Gulnar Tatymtayeva	Lawyer, Senior Officer, Department of Prevention and Interagency Cooperation, Drug Control Committee, Ministry of Interior

KYRGYZ REPUBLIC:

Mr. Abdykul uulu Mavlen	Head of Legal Analysis Unit, Penal Reform Department, Ministry of Justice.
Mr. Erik Iriskulbekov	Lawyer, Legal Clinic ADILET
Mr. Marat Jamankulov	Head of Penal Reform Department, Ministry of Justice
Mr. Zootbay Dobaev	Coordinator of Prison Programmes, Office of Prime-Minister
Ms. Gulzat Saadabaeva	Lawyer, Ministry of Health
Mr. Bogatyr Saparbaev	Head of Analysis and Management Unit, Chief Directorate for Punishment Execution (GUIN), Ministry of Justice

REPUBLIC OF TAJIKISTAN:

Mr. Mukhammad Aripov	Head Specialist, Legal Unit, Executive Office of the President of Republic of Tajikistan
Mr. Rakhimjon Makhmudov	Head, Legal Department, Ministry of Health
Mr. Vladimir Magkoev	Country Programme Coordinator, Drug Demand Reduction Programme, OSI
Mr. Azamjon Mirzoev	Deputy Minister, Ministry of Health
Mr. Jumaboi Sanginov	Member of the Committee on Social and Family Issues, Health Care and Ecology, Madjlisi Namoyandagon, Madjlisi Oli(Parliament), Head of Faction
Mr. Murtazokul Khidirov	Director, NGO "RAN"
Ms. Farangiz Yamakova	Senior Specialist, International and Legal Department, Ministry of Justice
Mr. Bakhrom Abdulkhakov	Deputy Chief, Department of Correctional Affairs, Ministry of Justice

TURKMENISTAN:

Mr. Tagandurdy Annamuradov	Head, Medical Department of Penitentiary System, Ministry of Interior
Ms. Gulyalek Bayramova	Leading Specialist, Lawyer, Department of International Relations and Law, Ministry of Interior
Ms. Altyngoze Divanova	Consultant, Lawyer, Legal Firm "Kopetdag- Lada"
Mr. Batyr Kulhanov	Senior Prosecutor, Department of International Relations, Office of Prosecutor General
Mr. Shamurat Hydyrov	First Deputy-Head, Penitentiary System Department, Ministry of Interior

REPUBLIC OF UZBEKISTAN:

Ms. Shoiri Umarova	Deputy-Chair, Committee on Labour and Social Issues, Oliy Majlis (Parliament)
Ms. Djamilya Niyazova	Member of Committee on Labour and Social Issues, Oliy Majlis (Parliament)
Ms. Irina Dudukina	Chief Legal Adviser, Ministry of Health
Mr. Makhmud Abduhalikov	Director, Legal Services Company "Al-Makhmud Maslahati"
Mr. Mumtoz Khakimov	Coordinator, Country Coordination Mechanism on AIDS
Mr. Nosir Djuraev	Epidemiologist, Expert, Republican AIDS Centre
Mr. Oybek Kayumov	Chief Doctor, Republican Hospital, General Directorate of Execution of Punishment, Ministry of Interior
Mr. Djamol Nuritdinov	Deputy-Chief Doctor, Republican Hospital, General Directorate of Execution of Punishment, Ministry of Interior
Mr. Oleg Mustafin	Chief Doctor, Tashkent-City Narcology Dispensary

The following UNODC National Project Officers (NPO) and Project Assistants (PA) supported in-country work of national experts in a variety of ways, commented on the drafts of their country's summary report prepared by the international consultant, and organized stakeholder meetings to discuss findings of the legislative analysis and seek government endorsement of the report's recommendations:

Ms. Arzu Guliyeva, NPO, Azerbaijan
Ms. Madina Takenova, NPO, Kazakhstan
Ms. Gyulnara Karpisheva, PA, Kazakhstan
Mr. Mirlan Mamyrov, NPO, Kyrgyzstan
Ms. Almira Manapbaeva, PA, Kyrgyzstan
Ms. Mutabara Vokhidova, NPO, Tajikistan
Ms. Annatach Mamedova, NPO, Turkmenistan
Mr. Akmal Rustamov, NPO, Uzbekistan
Ms. Irina Makarova, PA, Uzbekistan

Translation services for this publication (English-Russian and Russian-English) were provided by Elya Engelhardt, Liana Ibragimova and Olga Vovk. Some additional assistance with translation of final edits was provided by Alec Khachatryan. This publication is a result of the project TDRAC-I29 of UNODC whose funds consisted of contributions made by OFID, UNAIDS, Austria, Ireland, Italy and Sweden; in Kyrgyzstan and Tajikistan, some parts of this work were supported by DFID and OSI.

EXECUTIVE SUMMARY

PROJECT BACKGROUND

In recent years, the region of Eurasia has seen one of the world’s fastest-growing HIV epidemics, with unsafe drug injecting practices being a major driver. During the past decade, the region comprising countries of the former Soviet Union has experienced the highest increase in prevalence of drug use worldwide,¹ and UN agencies have recently estimated that injecting drug use accounts for more than 80% of all HIV infections in Eastern Europe and Central Asia.²

While the six countries participating in this legislative review and assessment — Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan — differ with regard to HIV prevalence and the extent of their responses to HIV, they have much in common. All of the countries face concentrated HIV epidemics driven predominantly by unsafe drug-injecting practices and there is significant potential for the further rapid spread of HIV in Central Asia and Azerbaijan. Between 2000 and 2007, the number of officially recorded HIV cases in the region of Central Asia increased 15-fold.³ Furthermore, according to local and international experts, official statistics may underestimate the real prevalence by a factor of ten.⁴

In countries that participated in the project, the spread of HIV is exacerbated by the high prevalence of other sexually transmitted infections (STIs). In addition to the fast-growing HIV epidemic, there is a severe tuberculosis (TB) problem in the region, a major contributor to deaths among people with immune system compromised by HIV; TB prevalence is particularly high among injecting drug users and prisoners.⁵ HIV in prisons is another specific area of major concern, and is linked heavily to injection drug use inside and outside prisons. While people who inject drugs and people in prison are heavily affected by HIV, they are poorly covered by HIV prevention and treatment services.

According to UN agencies, “[i]n most countries of Eastern Europe and Central Asia, where injecting drug use accounts for more than 80% of all HIV infections, needle and syringe programmes regularly reach only 10% of the estimated number of injecting drug users.”⁶ Despite the acknowledged effectiveness of interventions such as needle and syringe programmes and opioid substitution therapy, data suggest that the overall coverage by such services of people who inject drugs remains limited,⁷ and hundreds of thousands of people who use drugs do not have access to them because of legal and social barriers.

Legislative assessment and the need for human-rights based legislative and policy reform

In 2007-2008, under the auspices of the Regional Office for Central Asia of the United Nations Office on Drugs and Crime (UNODC), as part of the project *Effective HIV/AIDS prevention and care for vulnerable populations in Central Asia and Azerbaijan (2006-2010)*, an assessment of national legislation in Azerbaijan and five Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan) was conducted in order to strengthen national capacity to achieve universal access to services for HIV prevention and treatment, with a special focus on people who inject drugs and people in prison. The project was carried out by teams of experts from all six participating countries, with the UNODC Regional Coordinator and national staff and the Canadian HIV/AIDS Legal Network (“Legal Network”) serving as expert resources.

The assessment showed that there are many common issues of concern in the legislation and policies of the project countries. HIV prevention is not integrated into state health care systems (including health care services in prisons), meaning that health care professionals are often unfamiliar with effective, scien-

1 Central Asia: Kyrgyz Republic, Tajikistan and Uzbekistan – Regional Study on Drug Use and HIV/AIDS, Regional Summary (UNODC and World Bank, 2007), p. 16.

2 WHO, UNAIDS & UNICEF, *Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector: Progress Report 2008* (Geneva: WHO, 2008), p. 66.

3 UNODC (Regional Office for Central Asia), *Compendium of Drug-related Statistics 1997-2008* (June 2008), p. 32.

4 Ibid.

5 *Towards Universal Access* (2008), pp. 36-38.

6 *Towards Universal Access* (2008), p. 63.

7 *Towards Universal Access* (2008), p. 66-67, 69-70.

tific methods of HIV prevention and treatment of HIV-infection and other concomitant health disorders for people at risk. Services for vulnerable populations are fragmented, uncoordinated, and governed by vague rules and referral schemes. There are few or no official standards for providing harm reduction services. In addition, outdated national laws often impede evidence-based approaches to HIV prevention among vulnerable groups, in particular harm reduction measures, and complicate relationships between low-threshold HIV-related services and law enforcement bodies. Hundreds of thousands of people who use drugs and people in prison have limited or no access to prevention and health care services because of structural, legal and social barriers. If done correctly, with the objective of facilitating greater access to good-quality services, clear legislation and regulation could assist in scaling up evidence-based measures for HIV prevention and treatment.

As almost everywhere in the world, in the Central Asian countries and Azerbaijan people who use illegal drugs and people in prisons are often among the most marginalised and stigmatized groups of society. Given administrative and criminal penalties for drug use and possession of small amounts of drugs for personal use, people who use drugs are at high risk of ending up in prison. They are vulnerable to abusive law enforcement practices, high rates of incarceration, and the denial of health services (both outside and inside prisons).⁸ Inside prisons, people are often at higher risk of HIV infection, because of sharing drug-injection and tattooing equipment, as well as practicing unprotected sex, both consensual and non-consensual. Even countries that have invested heavily in drug interdiction efforts have not succeeded in stopping drug use in prisons.

It is widely recognized that responses to HIV and AIDS are much more efficient if human rights, particularly of those most vulnerable to HIV infection are protected: ensuring that law and policy are based on, and reflect, human rights norms and principles is essential, even though additional actions beyond just adopting sound law and policy are, obviously, also necessary to ensure the full enjoyment of human rights. A “rights-based approach” needs to be at the core of legislative review and reform, and such an approach will be of greatest benefit to public health.

International human rights treaties impose obligations on states to respect, protect, and fulfil a range of human rights, including in their national laws and policies. In the case of Azerbaijan and the Central Asian countries, these obligations include the obligation to take positive measures to realize, over time, the right to the highest attainable standard of health for all⁹ — this includes people who use drugs and incarcerated people. The project countries have also committed to respecting and protecting numerous civil and political rights of great relevance to an effective response to HIV, including the rights to life, security of the person and privacy, to freedom of expression and association, as well the right to receive information.¹⁰ Furthermore, underlying the entire body of international human rights law is the fundamental principle of non-discrimination, of particular relevance to people living with HIV and to those groups and individuals such as people who use drugs and people in prison, whose marginalization and exclusion, including through legally-sanctioned discrimination contributes to their vulnerability to HIV and to hindering their access to health and other services.

8 See more in D. Barrett et al., *Recalibrating the Regime: The Need for a Human Rights-Based Approach to International Drug Policy* (London: The Beckley Foundation Drug Policy Programme, 2008).

9 *International Covenant on Economic, Social and Cultural Rights*, UN General Assembly, 993 UNTS 3 (1966) (entered into force 3 January 1976), Article 12; UN Committee on Economic, Social and Cultural Rights, *General Comment 14: The right of everyone to the enjoyment of the highest attainable standard of physical and mental health*, UN Doc. XXX (2000).

10 *International Covenant on Civil and Political Rights*, UN General Assembly, 999 UNTS 171 (1966) (entered into force 3 January 1976), Articles 6, 17, 19, and 22.

OUTLINE OF REPORT

This publication consists of several components, as follows:

- Part I consists of an integrated report synthesizing key findings, concerns and recommendations emerging from the national legislative reviews and analyses in the six countries that participated in the project.
- Part II contains a detailed report for each of the six countries. Each report provides a description of the currently available evidence and the country's existing laws and policies of greatest relevance to HIV among people who use drugs and incarcerated people, and presents detailed recommendations for legislative and policy reform aimed at strengthening the country's response to HIV among these vulnerable populations.
- Part III contains a series of appendices which provide additional information about the project, and tools that can be used by legislators, policy-makers and others in implementing these recommendations.

PART I - INTEGRATED REPORT

The integrated report consists of six sections. The **first section** provides an overview of the project and its methodology. The **second section** provides general background information about the project countries, including a summary overview of the situation with HIV and AIDS and with drug use among the population as a whole and in prisons specifically.

The remaining four sections delve into specific areas of concern. Each of these sections is divided into the following sub-sections: (a) an overview of the situation; (b) the rationale for reform; and (c) recommendations for reform.

Section three presents information on administrative and criminal law issues related to drug use and non-violent drug-related offences. The assessment showed that in each of the six project countries, the law and its implementation reflect a punitive approach towards people who use drugs, and the national response to drugs accords a predominant role to law enforcement agencies, rather than health agencies. This approach often ignores evidence-based methods of HIV prevention and treatment and international standards of drug dependence treatment, and often contradicts public health interests.

Each country maintains administrative and criminal law prohibitions on drugs, and defines minimum and maximum amounts of narcotic drugs and psychotropic substances, the possession of which leads to administrative or (more often) criminal punishment. The project countries vary in how they define various small or large quantities of drugs, and the penalties associated with the different amounts, with Uzbekistan and Kazakhstan having stricter limits and harsher penalties and Tajikistan taking a somewhat more liberal approach.¹¹

In most of the project countries, the national legislation makes a distinction between people who use drugs and people who deal drugs, by adopting the concepts of possession "for sale" and "not for sale". Azerbaijan is the only country whose law explicitly reflects the notion of possession "for personal use".¹² Drug *use per se* is formally prohibited in a number of the project countries, although it is not always penalized (e.g. with a specific penalty under the country's administrative or criminal code).¹³

11 For example, any quantity of heroin in Uzbekistan is classified as "large", while Kazakhstan's approach is effectively the same, defining any amount of heroin greater than 0.01 gram as "large".

12 In other countries, the law on drugs does not reflect the concept of possession for "personal use" or permissible possession of a quantity that is based on an "average single dose".

13 Legislation in Azerbaijan provides for administrative liability for drug use. In Tajikistan and Turkmenistan, drug use without a doctor's prescription is prohibited according to the laws on drugs, but there is no penalty defined in administrative or criminal codes. In Kazakhstan and Kyrgyzstan, drug use in public places leads to administrative penalty; possession of insignificant quantities of a narcotic substance in Kazakhstan may entail criminal charges. Uzbekistan does not have either administrative or criminal liability for drug use, nor does the law on drugs state any prohibition of it.

In general terms, the objective of recommendations for reforming administrative and criminal law in the project countries is the humanization of policies related to drug use and to non-violent drug related offences by:

- repealing administrative liability for mere drug use and administrative and criminal liability for possession of small amounts of drugs not for the purpose of sale;
- ensuring that harm reduction programmes are not prosecuted for "incitement of drug use", drug "propaganda", operating a "site for drug consumption" or similar offences;
- widening the spectrum of alternatives to imprisonment for those convicted of non-violent drug-related criminal offences and limiting the use of pre-trial detention; and
- prohibiting random compulsory referral for drug testing by law enforcement authorities.

In addition, the legislative analysis identified other areas of criminal and administrative law that may hinder an effective response to HIV among other vulnerable groups in addition to people who use drugs or are in prison — namely, the criminalization of marginalized groups such as sex workers and, in two countries, men who have sex with men, as well as the specific targeting of HIV transmission and exposure for criminal prosecution. These approaches run contrary to international human rights standards and/or international policy recommendations. This section of the Integrated Report presents a detailed rationale for these reforms and general recommendations on these issues, with more detailed, country-specific recommendations in the individual country reports (Part II).

Section four presents information about legislation related to health care systems and services. In each of the project countries, health care is guaranteed by the state. As stated in the law, it is provided free-of-charge according to place of permanent residence based on a certificate of domicile. However, in all six countries that participated in the project, people who use drugs have limited access to health care and HIV prevention. Harm reduction services are rare, marginalised, and not integrated into legislation and governmental policies.

Typically, drug dependence treatment in all six countries is aimed at full abstinence, and consists largely of detoxification and some non-standardized psychosocial interventions; access to other treatment methods and options recommended by international organizations is limited at best or simply non-existent. The effectiveness of this system is low, according to clients interviewed by national expert groups in some of the project countries¹⁴ and, according to data provided by the national expert groups, it is not well evaluated officially. Although opioid substitution treatment (OST) is becoming increasingly available globally, in two countries that participated in the analysis (Tajikistan and Turkmenistan) it is still not available, the single pilot OST project was cancelled in Uzbekistan in 2009, and in the other three countries (Azerbaijan, Kazakhstan and Kyrgyzstan) the coverage remains low.¹⁵

Compulsory drug dependence treatment in one form or another exists in all six countries that participated in the study — both in the community and in prison. The law generally allows for compulsory treatment of people with alcoholism and drug dependence who refuse to undergo "voluntary" treatment and whose behaviour disturbs public order or threatens the well-being of others. In all of the project countries, narcological facilities under the purview of the Ministry of Health provide compulsory treatment for non-offending drug-dependent people. Turkmenistan also maintains a so-called treatment-labour camp (*лечебно-трудовой профилакторий*) run by the Ministry of Interior. The level of compulsory treatment of drug dependence for non-offenders varies in the project countries: in Tajikistan, Azerbaijan and Kyrgyzstan, there is in practice little or no enforcement of such compulsory treatment, whereas in Kazakhstan, Turkmenistan and Uzbekistan, each year an estimated 6-13% of all persons undergoing drug dependence treatment are doing so under compulsion, according to UNODC (UNODC, 2009, unpublished data). Compulsory drug dependence treatment for prisoners is used in all countries participating in the project.¹⁶

In all of the project countries, it is standard practice to *register* the names and other information about people who use controlled substances and people with drug dependence at narcological facilities. The

14 Interviews conducted by the expert groups of Kazakhstan and Uzbekistan; see also: Human Rights Watch, *Fanning the Flames: How Human Rights Abuses are Fuelling the AIDS Epidemic in Kazakhstan* (2003).

15 See summary country reports.

16 Provisions for compulsory drug treatment are established by specific laws on compulsory treatment (e.g., in the case of Tajikistan, Turkmenistan and Uzbekistan), by special sections in the countries' *Criminal Codes* governing drug dependence treatment in prisons; and national laws on drugs.

existing legal provisions that regulate registration of people who use drugs at medical facilities allow for numerous negative consequences of registration, including exposing registered persons to legally-sanctioned discrimination in such areas as employment and/or education.

Many of the national HIV policies in the project countries are outdated, with wide provisions for mandatory or compulsory HIV testing. Although national HIV laws may only explicitly mention mandatory or compulsory testing for HIV in some limited circumstances (e.g., blood donors, foreign nationals), they generally fail to prohibit explicitly the broader application of involuntary testing. It is often ministerial or departmental guidelines, orders or instructions that expand the categories of people who are subject to HIV testing that is not fully voluntary. There are also frequent breaches of confidentiality regarding HIV status of those tested.

This section first puts forward some recommendations aimed at eliminating systemic barriers to access to health care services. It also identifies ways in which the project countries should update existing or adopt new national laws and strategies in the areas of HIV and of drugs, so as to ensure that:

- the country's responses to the interconnected health problems of HIV and of drugs address the particular vulnerability of people who use drugs and people in prisons, including through guaranteeing easy access to effective services for preventing and treating drug dependence and reducing the harms associated with drug use;
- civil society and vulnerable groups are involved in the development, implementation and evaluation of these national policies and programmes on HIV and on drugs; and
- health workers and law enforcement personnel have an informed understanding of HIV, drug dependence and harm reduction, as well of human rights, so that their work would contribute to an effective response.

In addition, this section puts forward some detailed recommendations regarding the legislative basis for (1) drug dependence treatment, and (2) HIV prevention and treatment, with a particular focus on people who use drugs. It is recommended to amend national legislation, policies, regulations, guidelines and protocols to guarantee:

- the universal availability and accessibility of a variety of voluntary treatment options for drug dependence, including easy access to opioid substitution treatment (OST);
- the application of compulsory drug dependence treatment only as a measure of last resort and, if applied, in full compliance with human rights principles and WHO recommended clinical protocols;
- full confidentiality of patients' identity and health information, and the prohibition of using information from medical records of people who use and/or are dependent on drugs (i.e., from narco-logical registries) for reporting, without the explicit and documented informed consent of the patient.

Recommendations regarding HIV prevention and treatment include the development of legal, regulatory and policy provisions that will:

- ensure universal access to HIV testing, accompanied by quality pre- and post-test counselling, that is fully voluntary, informed and strictly confidential (and mandate access to truly anonymous HIV testing in at least some settings);
- explicitly prohibit mandatory and compulsory HIV testing (with the exception of mandating testing of donors of blood, organs, tissue or other bodily substances);
- guarantee full confidentiality of medical information, including HIV test results, and ensure that there are effective, accessible means of legal redress for persons whose right to confidentiality of medical information is violated;
- guarantee easy access to HIV-related care, including antiretroviral treatment (ARV) and especially for people who use drugs and people in prison who are HIV-positive; and
- guarantee easy access to TB services for drug dependent people and people living with HIV, including by integrating TB and HIV-related health care.

Section five examines access to health services in prisons, particularly HIV prevention and treatment.

There were an estimated 135,000 people in prison in the project countries in 2008; a significant percentage of them were serving a sentence for drug-related offences.¹⁷

In some of the project countries, drug use in prison is recognized by the authorities (e.g., Kyrgyzstan, Kazakhstan, Tajikistan), but there remain very few prison-based programmes to protect people who inject drugs from infectious diseases and other harms. Bleach is provided in most of the project countries, but it appears that prisoners are not given information about the most effective use of bleach to clean equipment used for drug injection (or tattooing), and are not allowed to seek and use bleach confidentially. UN agencies and other health experts widely recognize that provision of bleach is a sub-standard measure and not a substitute for access to sterile injection or tattooing equipment. With respect to harm reduction services other than provision of bleach, Kyrgyzstan's policies are the most advanced of the six project countries: both OST and needle and syringe programmes exist in the country's prisons. At this writing, these programmes are not available in prisons in the other project countries.

According to some country reports, prisoners often have to pay for medication and personal hygiene products, and access to specialised health care (STI treatment, dental care, etc.) is limited or unavailable.

In all the project countries, people in prison are subject to compulsory drug dependence treatment. Courts commonly order compulsory treatment as part of sentencing, in addition to other criminal penalties — even though international drug control treaties explicitly allow for *alternatives* to conviction and incarceration for drug offences, including providing treatment and rehabilitation services as alternatives, instead of imposing these *in addition to* criminal penalties.¹⁸ According to national laws, voluntary drug dependence treatment in prisons is provided in almost all project countries (with the exception of Turkmenistan). However, the national experts note that in reality very few people in prison who need drug dependence treatment undergo it voluntarily.

In all of the project countries, the law allows for compassionate release from prison of people with terminal illness; generally, this is thought to be available to at least some patients diagnosed with AIDS, although usually AIDS is not specifically mentioned. There are specific, discriminatory restrictions on the rights of prisoners with HIV and/or prisoners who have not completed compulsory drug dependence treatment, such as denying eligibility for transfer to prisons with less strict security regimes.

In general terms, the recommendations in this section aim at strengthening the response to HIV in prisons by developing norms and regulations that will:

- include HIV prevention and treatment in prisons in national strategies and programmes and specify clear funding sources for these measures;
- ensure the availability and accessibility of adequate health care services in prisons;
- make national health authorities responsible for prison health (as opposed to the Ministry of Justice or the Ministry of Interior), in order to make it easier to guarantee that people in prison are entitled to the same efforts to protect and promote health, and to the same health services, as people outside prisons;
- regulate the provision of information about HIV and AIDS and training for both prison staff and prisoners;
- ensure easy, confidential access to disinfectants such as bleach and to sterile injection and tattooing equipment;
- introduce easy access to voluntary drug dependence treatment (including OST) in prisons and limit the use of compulsory drug dependence treatment in prison settings;
- ensure access to antiretroviral treatment (ARV) in prison;
- ensure access to voluntary and confidential HIV testing, with counselling and informed consent, in prisons; and
- enable NGO contributions to HIV prevention and care in prisons, as well as supporting people in prisons to do peer HIV education and outreach to other prisoners.

¹⁷ An estimated one-third of those in Tajikistan in prison had previously injected drugs and according to the national expert group, one-third were serving sentences for drug-related offences at the time of their review in 2007. 21.4% of people in prison were serving drug-related sentences in Uzbekistan.

¹⁸ *Single Convention on Narcotic Drugs*, 1961, UN, 520 UNTS 331, as amended by the 1972 Protocol, Article 36(2); *Convention on Psychotropic Substances*, 1971, UN, 1019 UNTS 175, Article 22; *Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances*, 1988, Article 3(4).

Section six provides information and recommendations regarding legislative discrimination and other restrictions of rights of people living with HIV or vulnerable to HIV. All six of the project countries have general anti-discrimination provisions in their Constitutions and other legislation. However, there are no specific statutes to prohibit discrimination; rather, discriminatory acts towards certain groups may be prohibited in laws concerning these groups. Employment laws may also contain non-discrimination clauses, while health laws may contain non-discrimination clauses and/or the obligation on health care professionals to render medical care to everyone. In some project countries, the violation of such non-discrimination (or equality) clauses is penalized by that country's *Criminal Code*. Similarly, in some of the countries, legislation establishes the possibility of criminal liability for a discriminatory refusal to provide medical services.

Nevertheless, contradicting such prohibitions, discrimination is often formally permitted by the law in areas such as employment and education, family life and some other areas. A number of the countries formally prohibit people who are living with HIV and people who use drugs from working in certain occupations or positions. In case of HIV infection, such prohibitions are often accompanied by — and made operational through — mandatory HIV testing for people working in, or applying to work in, certain positions. In some project countries, people seeking to enrol in vocational training and higher education institutions are required to present a medical certificate, which includes a number of points (such as not being on the registry as a person who uses drugs or is dependent on drugs or alcohol, and may in certain cases include HIV status). In countries where HIV testing is required in order to enrol in some types of educational institutions, such as a military academy, this provision infringes the right to education.

Many of the project countries deport non-citizens living with HIV. This practice is sometimes associated with — and made operational through — mandatory HIV testing of foreigners and stateless persons. There are also restrictions on the right to found a family, such as when a government resolution lists the diseases that automatically prevent someone from adopting children (the list includes both HIV and drug dependence).

Recommendations to address such discrimination embedded in the law include the development or elaboration of provisions that would:

- strengthen existing legislative protections against HIV-based discrimination where there are gaps;
- introduce legal protection against discrimination based on drug dependence;
- recognize both HIV infection and drug dependence as disabilities for at least some legal purposes (e.g., protection against discrimination based on disability); and
- eliminate unjustified restriction or denial of rights of people who use drugs and people living with HIV such as unjustified discrimination in employment and educational institutions, immigration policies and in family relations.

PART II - COUNTRY REPORTS

Part II of this publication consists of six individual country reports, arranged following the same general structure as the Integrated Report — a general overview of the country's legal system; its administrative and criminal laws related to drugs; access to health care services, including drug dependence prevention and treatment and HIV prevention and treatment (with a focus on people who use drugs); specific issues related to HIV prevention and treatment in prisons; and anti-discrimination provisions. Each individual country report concludes with a detailed set of recommendations tailored specifically to the country's context, including current legislation and policy. These individual country reports, while lengthy and detailed, are distilled from the more detailed legislative assessment conducted by each of the six national expert groups and additional material gathered by those groups, the project's technical advisors and UNODC staff.

PART III – APPENDICES

Part III contains a number of appendices, which include the assessment tool used by the national expert groups, the teaching module delivered to guide these groups in their assessments, and tables with some country data that will be of interest to national policy-makers, researchers and various specialists, as well

as a glossary of terms used in the report.

Key findings and conclusions

In summary, the assessment of national laws and policies in relation to people who use drugs and prisoners showed that there are issues common to all six countries in achieving universal access to HIV prevention and treatment. All countries have national laws that hinder the implementation of evidence-based approaches to preventing and treating HIV among vulnerable groups such as prisoners and people who use drugs. Current attitudes and policies sometime contribute to complicating interaction between HIV prevention services and law enforcement agencies. In general, the main issues that have been identified by the countries' expert teams and the international experts can be considered to fall into the following broad categories:

- punitive drug policies towards people who use drugs including their incarceration (sometimes for possession of very small amounts of drugs) and few or no alternatives to incarceration for people who use drugs in the case of non-violent offences;
- limitations of the rights of people living with HIV, people who use drugs, and prisoners with HIV and/or drug dependence, and no effectively enforceable anti-discrimination provisions;
- broad provisions for non-voluntary medical interventions such as coercive drug testing, compulsory treatment of drug dependence, and mandatory HIV testing;
- absence of regulatory frameworks that clearly enable and support evidence-based HIV prevention interventions, including harm reduction services, that results in low access of people who use drugs and incarcerated persons to effective HIV prevention and treatment interventions;
- insufficient availability of effective drug dependence treatment services, especially of opioid substitution treatment (i.e. no OST in some countries or low capacity pilot programmes in a few others), and limited or no rehabilitation and overdose prevention programmes in communities and in prisons; and
- limited meaningful participation of civil society, including groups of people living with HIV, people who use drugs and prisoners in the development, implementation and evaluation of the effectiveness of national strategies and laws on both HIV and on drugs.

This report should assist national policy-makers and legislators to revisit laws and policies governing the accessibility of health care in general and of HIV-related services in particular — including those regulating drug dependence treatment and access to health care in custodial settings — and to develop them in line with best, evidence-based practices and human rights principles. Amendments should be developed for health care laws (confidentiality, informed consent to medical procedures and treatment, limiting the use of coercive medical measures), HIV laws (HIV testing, repeal of discriminatory practices), social protection and family legislation (disability, child custody and adoption, deprivation of parental rights), and administrative and criminal laws (provisions on drug use/possession for personal use, alternatives to imprisonment, compulsory treatment of drug dependence). The recommendations should also be reflected in national programmes on HIV, tuberculosis, drug control, and criminal justice/penal reform. To make these recommendations operational it will be necessary to align regulations and implementing practices with the amended laws. This will allow for the introduction and improvement of protocols and standards of services, improvements in reporting and accountability of services, and improved professional education and vocational training. These reforms will contribute to the protection of people living with HIV, people who use drugs and prisoners from violations of their rights, including discrimination and punishment on the ground of their health status, while providing for universal access to evidence-based health interventions. The reforms will make national legislation and norms compliant with states' obligations to respect, protect and fulfil the human rights of these populations, including their right to health — and, therefore, ultimately will benefit the public health and society's well-being as a whole.

I. INTEGRATED REPORT

1. INTRODUCTION

1.1 BACKGROUND TO THE PROJECT

This report covers six countries of the former Soviet Union: Azerbaijan and the five Central Asian countries of Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan who have participated in the UNODC-supported project “Effective HIV prevention and care among vulnerable populations in Central Asia and Azerbaijan” (2006-2010).

While the project countries differ with regard to HIV prevalence and the extent of their responses to HIV, they have much in common. According to the United Nations, in recent years the region has experienced one of the world’s fastest growing HIV epidemics, resulting mainly from unsafe drug-injecting practices.¹⁹ While people who inject drugs account for approximately 10% of HIV infections globally, in Central Asia and Eastern Europe injecting drug use accounts for more than 80% of all HIV infections.²⁰ All of the countries face concentrated HIV epidemics, with the prevalence of HIV infection among injecting drug users reaching 33 per cent in some urban sites.²¹

There is also significant potential for the further rapid spread of HIV in Central Asia and Azerbaijan. Between 2000 and 2007, the number of officially recorded HIV cases in the region of Central Asia increased 15-fold.²² As of 2008, roughly 2 million people were living with HIV in the countries of the former Soviet Union, indicating a 20-fold increase in HIV incidence in less than a decade.²³ Between 2000 and 2003, the annual number of new HIV infections tripled in Kyrgyzstan and Azerbaijan, and grew nine-fold in Kyrgyzstan, 16-fold in Uzbekistan and 17-fold in Tajikistan.²⁴ Furthermore, according to local and international experts, official statistics may underestimate the real prevalence by a factor of 10.²⁵ In addition to the fast-growing HIV epidemic, there is a serious tuberculosis (TB) problem in the region, a major contributor to deaths among people with immune systems compromised by HIV; TB prevalence is particularly high among injecting drug users and prisoners. According to UN data, in 2008 multidrug-resistant TB had reached the highest rates ever encountered. Azerbaijan and Uzbekistan were among the countries reporting the highest prevalence rates.²⁶

HIV in prisons is another specific area of major concern, and is intimately linked to injection drug use. For example, in Tajikistan there are reports of HIV transmission in prisons: according to official data, HIV prevalence among prisoners in two surveillance cities (Dushanbe and Khujand) increased from 6.2% in 2005 to 8.4% in 2006.²⁷ In Uzbekistan, the highest prevalence rates of HIV are found among prisoners.²⁸ In Kyrgyzstan, the reported cumulative number of HIV cases in prisons in 2007 was almost 120 times the national average. It is reported that 60% of prisoners use drugs while incarcerated, with the majority injecting.²⁹ While people who inject drugs and prisoners are heavily affected by HIV, they are poorly covered by HIV prevention and treatment services. Globally, an estimated 15.9 million (range 11.0 – 21.2 million) people

19 Central Asia: Kyrgyz Republic, Tajikistan and Uzbekistan – Regional Study on Drug Use and HIV/AIDS, Regional Summary (UNODC and World Bank, 2007), p. 16 [hereinafter “Central Asia Regional Study on Drug Use and HIV/AIDS”].

20 WHO, UNAIDS & UNICEF, *Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector: Progress Report 2008* (Geneva: WHO, 2008), p. 66.

21 N. Kerimi, “Accessibility of opioid substitution treatment in countries of Central Asia and in Azerbaijan: recent developments and next steps,” Presentation at the 4th Central Asian Partnership Forum on HIV infection (Almaty, Kazakhstan, 9-10 November 2009).

22 UNODC (Regional Office for Central Asia), *Compendium of Drug-related Statistics 1997-2008* (June 2008), p. 32.

23 UNAIDS & WHO-Europe, *Policy Brief: Progress on implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia* (2008), p. 5.

24 UNDP, Central Asia Human Development Report — “Bringing down barriers: Regional cooperation for human development and human security,” Central Asia Human Development Report (2005), p. 146 [hereinafter “Central Asia Human Development Report 2005”].

25 Ibid.

26 *Towards Universal Access* (2008), pp. 36-38.

27 National progress report on the Declaration of Commitment on HIV/AIDS to the Special Session of the UN General Assembly: Tajikistan 2007 [Национальный доклад о ходе выполнения декларации о приверженности делу борьбы с ВИЧ/СПИД Специальной Сессии Генеральной Ассамблеи ООН] (presented 31 January 2008).

28 See summary report for Uzbekistan below in Part II.

29 Central Asia Regional Study on Drug Use and HIV/AIDS, p. 36.

inject drugs, and an estimated 3.0 million (range 0.8 – 6.6 million) of them are living with HIV.³⁰ Despite the acknowledged effectiveness of interventions such as needle and syringe programmes (NSPs) and opioid substitution therapy (OST), data suggest that the overall coverage by such services of people who inject drugs remains limited,³¹ and hundreds of thousands of people who use drugs do not have access to them because of legal and social barriers.

According to UN agencies, “[i]n most countries of Eastern Europe and Central Asia, where injecting drug use accounts for more than 80% of all HIV infections, needle and syringe programmes regularly reach only 10% of the estimated number of injecting drug users.”³² In 2007, the best results in the region were reported from Tajikistan and Uzbekistan, which managed to exceed the threshold of at least one needle and syringe programme site per 1000 drug injectors, comparable to coverage achieved by all high-income countries in Europe.³³ Although countries are increasingly scaling-up access to opioid substitution treatment, as of December 2009, it was still not available at all in two countries that participated in the project (Tajikistan and Turkmenistan), and consisted of only two pilot programmes introduced in 2008 in another (Kazakhstan). In Azerbaijan and Kyrgyzstan, coverage remains low, and in Uzbekistan, in June 2009 the government discontinued its pilot OST project.³⁴ As for access to antiretroviral (ARV) therapy, in 2006 in Eastern Europe and Central Asia, approximately 79% of reported HIV cases were among people who injected drugs, but they represented only 39% of people receiving ARV therapy.³⁵

The countries participating in this project generally have a variety of statutory provisions and other legal instruments on HIV as well as national plans and strategies on both HIV and drug use. Often, these remain but provisions on paper, without adequate resources for their implementation, and do not provide real protection to vulnerable and at-risk populations. Furthermore, partly because of the absence of clear legal regulations on HIV-related preventive interventions for most at risk groups (such as people who inject drugs), often HIV prevention and treatment services (including in prisons) are not well integrated into the broader state health care system, as theoretically only AIDS centres are responsible for HIV prevention and treatment. As a result, most health professionals are unfamiliar with evidence-based effective methods of HIV prevention and treatment for people at risk, and services meant for vulnerable populations are fragmented, uncoordinated and governed by vague rules and referral schemes. There are few official standards for providing harm reduction interventions. Outdated or inadequate national legislation impedes scaling up evidence-based approaches to HIV prevention among vulnerable groups, in particular harm reduction measures, and complicates relationships between staff of HIV-related services and law enforcement personnel.

Finally, in most of the project countries, the national legislative and policy approach is to treat drugs, and the people who use them, predominantly as objects of criminal and other coercive measures, rather than recognizing drug use primarily as a health matter and framing the response accordingly as an individual and public health concern. As a result, the formulation and implementation of legislation and other legal instruments often does not take into account the consequences and influence on the lives and status of vulnerable and marginalised groups or on public health more broadly.

This report focuses on people who inject drugs and people in prison, two populations particularly vulnerable to HIV, and presents results of a comprehensive assessment and analysis of relevant national legislation in the six project countries. The document gives a set of recommendations for the legislative and policy reforms necessary to remove barriers and enhance access of these marginalised groups to HIV prevention, care, treatment and support to help countries to fulfil their commitments to achieve universal access to HIV related services for their populations.

30 B.M. Mathers et al., “Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review,” *Lancet* 2008; 372: 1733-1745.

31 *Towards Universal Access* (2008), p. 66-67, 69-70; B.M. Mathers et al., “HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage,” *Lancet* 2010; 375: 1014-1028.

32 Ibid. “Regular reach” is defined as contact at least once per month: *ibid.*, p. 63.

33 Ibid., p. 67.

34 For more details, see individual country reports in Part II.

35 WHO-Europe & UNAIDS, *Progress on implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia* (2008), pp. 79-80.

1.2 RATIONALE FOR LEGISLATIVE REFORM AND THE IMPORTANCE OF HUMAN RIGHTS-BASED POLICY

“Reliance on criminal sanctions as the major response to illicit drug use inevitably results in the denial of human rights of the IDU [injecting drug user] population as drug use remains defined as a law enforcement rather than a health problem. Poor health outcomes in this population then follow, because health promotion and health care services are more difficult to provide to a now stigmatized and underground population. Protection of human rights is an essential precondition to improving the health of individual drug users and improving the public health of the communities where they live.”

A. Wodak, “Health, HIV Infection, Human Rights, and Injecting Drug Use,” *Health and Human Rights* 1998; 2(4): 24–41.

In their 2000 *Millennium Declaration*, UN Member States resolved, among other commitments, to have halted and begun to reverse the spread of HIV by the year 2015.³⁶ In the 2001 *Declaration of Commitment on HIV/AIDS* adopted by the UN General Assembly, all countries recognized that the realization of human rights and fundamental freedoms for all is an essential element of a global response to the HIV pandemic, including in the areas of prevention, care, support and treatment, and that it reduces vulnerability to HIV and prevents stigma and related discrimination against people living with or at risk of HIV infection.³⁷ Five years later, in 2006, in their *Political Declaration on HIV/AIDS*, UN member states reaffirmed the earlier commitments to overcoming legal, regulatory or other barriers that block access to effective HIV prevention, treatment, care and support, including access to medicines and other commodities and to services.³⁸ UN Member States committed to striving to achieve the goal of “universal access” to HIV prevention, treatment, care and support by 2010.³⁹ It is now widely accepted that responses to HIV and AIDS are much more efficient if the human rights, particularly of those most vulnerable, are protected.

Such commitments are especially relevant to the effort to ensure universal access for vulnerable groups such as people who use drugs and prisoners, given the key role that laws and policies, and their implementation, play in affecting these groups’ access to the means of HIV prevention and to adequate HIV care. Traditionally, policies on drug use have focussed on reducing both the supply of and demand for narcotic substances. Yet it has been documented repeatedly that supply and demand reduction policies that are primarily or wholly dependent on enforcing criminal prohibitions on drugs and drug use lead to a whole range of negative impacts on the health and the human rights of people who use drugs.⁴⁰ International human rights standards oblige States to respect, protect and fulfil the full range of human rights, including the right to the highest attainable standard of health, for all, which includes people who use and/or are dependent on drugs and people in prison. When human rights are disrespected, unprotected or unfulfilled — particularly for groups most at risk, such as injecting drug users and prisoners — this impedes efforts to prevent the spread of HIV and to ensure access to care, treatment and support for those with HIV, and this ultimately negatively affects public health generally.

As with other areas of law and policy, efforts to decrease supply and demand of drugs must be consistent with States’ human rights obligations, and to be sound public policy, must also be balanced with effective and proven measures to protect the health of people who use drugs and the public as a whole, including harm reduction interventions.⁴¹ There is, therefore, an urgent need in the countries of the region to review — and in many cases, reform — national legislation and policy, taking into account its influence on the status of people who use drugs and prisoners, on their access to information, tools and services for HIV prevention, care, treatment and support. Obviously, legislative and policy reform is not a panacea for preventing or treating HIV infection among people who use illegal drugs, prisoners or other at-risk populations. However, while it may not be sufficient on its own, it is a necessary but often neglected element of a comprehensive response to the epidemic.

36 *United Nations Millennium Declaration*, UN General Assembly Resolution 55/2, UN Doc. A/RES/55/2 (2000), para 19.

37 *Declaration of Commitment on HIV/AIDS*, UN General Assembly Resolution S-26/2, UN Doc. RES/S-26/2 (2001).

38 *Political Declaration on HIV/AIDS*, UN General Assembly Resolution 60/262, UN Doc. A/RES/60/262 (2006), para. 20.

39 *Ibid.*

40 E.g., see *At What Cost?: HIV and Human Rights Consequences of the Global “War on Drugs”* (New York: Open Society Institute, 2009); D. Wolfe & K. Malinowska-Sempruch, *Illicit Drug Policies and the Global HIV Epidemic: Effects of UN and National Government Approaches* (New York: Open Society Institute, 2004).

41 D. Barrett et al., *Recalibrating the Regime: The Need for a Human-Rights Based Approach to International Drug Policy*, The Beckley Foundation Drug Policy Programme, Report Thirteen (2008), online via www.aidslaw.ca/drugpolicy.

Efforts to address HIV epidemic should be based on human rights and aimed at enhancing public health

In their national legislation, countries are required to take into account their obligations under international law and respect, protect and fulfil human rights, such as the following obligations of particular relevance to the response to HIV and AIDS:

- According to the *Charter of the United Nations*, all countries that belong to the UN have a binding treaty obligation “to take joint and separate action” to achieve the purpose of the UN, including promoting “universal respect for, and observance of, human rights and fundamental freedoms for all.”⁴²
- The *Universal Declaration of Human Rights* declares that “everyone has the right to a standard of living adequate for health and well-being,” including “medical care and necessary social services.”⁴³
- States that are parties to the *International Covenant on Economic, Social and Cultural Rights*, including all six of the project countries, have recognized the right of every person to enjoy “the highest attainable standard of physical and mental health.”⁴⁴ These States have a binding legal obligation to take steps to realize fully this right, including those steps “necessary for ... prevention, treatment and control of epidemic, endemic ... and other diseases” and “the creation of conditions which would assure to all medical services and medical attention in the event of sickness.”⁴⁵ The UN Committee on Economic, Social and Cultural Rights, the expert body charged with assessing states’ compliance with their obligations under the ICESCR, has explained that “the right to health must be understood as a right to the enjoyment of a variety of facilities, goods, services and conditions necessary for the realization of the highest attainable standard of health.”⁴⁶
- In addition, the *International Covenant on Civil and Political Rights* (ICCPR) states that every person has the inherent right to life.⁴⁷ The Human Rights Committee, the expert body charged with addressing states’ compliance with their obligations under the ICCPR, has explained that this right “should not be interpreted narrowly” and that governments must adopt positive, proactive measures to protect human life, including measures that can help reduce the spread of epidemics.⁴⁸

Translating these and other human rights norms into practical actions in the context of HIV is the purpose of the *International Guidelines on HIV/AIDS and Human Rights*, originally produced by the Office of the UN High Commissioner for Human Rights (OHCHR) and UNAIDS in 1998 and updated in 2006. The Guidelines provide expert guidance to states on how to respond to HIV and AIDS through legislation, policies and practice that protect human rights and achieve public health goals. Of particular note, the *International Guidelines* recommend that harm reduction measures (e.g., clean injection equipment) be part of efforts to prevent HIV infection among injecting drug users and prisoners, and that the criminal law in particular should be reviewed to ensure that it is not an impediment to such measures.⁴⁹

Countries participating in this project have themselves recognized the importance of addressing HIV among injecting drug users and in prisons, including with harm reduction measures. The *Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia*, signed by heads of states and governments in February 2004, reaffirmed the fundamental importance of human rights “to preventing transmission of HIV, reducing vulnerability to infection and dealing with the impact of HIV/AIDS.”⁵⁰ Recognising

42 *Charter of the United Nations*, UNTS 993 (entered into force 24 October 1945), Articles 55, 56.

43 *Universal Declaration of Human Rights*, UN General Assembly, Resolution 217 A(III), UN GAOR, 3rd Sess., Supp. No. 13, UN Doc. A/910 (1948) 71, Article 25.

44 *International Covenant on Economic, Social and Cultural Rights*, UN General Assembly, 993 UNTS 3 (1966) (entered into force 3 January 1976), Article 12 [hereinafter ICESCR].

45 ICESCR, Article 12.

46 UN Committee on Economic, Social and Cultural Rights, *General Comment 14: The right to the highest attainable standard of health*, UN Doc. E/C/12/2000/4 (2000).

47 *International Covenant on Civil and Political Rights*, UN General Assembly, 999 UNTS 171 (1966) (entered into force 3 January 1976), Article 6 [hereinafter ICCPR].

48 UN Human Rights Committee, *General Comment 6: The right to life* (Art. 6), UN Doc. HRI/GEN/1/Rev.1 (1982) at p. 6.

49 Office of the High Commissioner for Human Rights & UNAIDS, *International Guidelines on HIV/AIDS and Human Rights* (2006 Consolidated Version), para. 21(d)-(e).

50 *Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia*, signed 24 February 2004, online: http://www.euro.who.int/aids/treatment/20051018_1.

that in the region prisoners and people who inject drugs are among those at highest risk of HIV, the Declaration set out participating countries’ commitment to promote, enable and strengthen the widespread introduction of HIV prevention, drug dependence treatment and harm reduction programmes — such as needle and syringe programmes, bleach and condom distribution, voluntary HIV counselling and testing, opioid substitution therapy, and STI diagnosis and treatment — in line with national policies.⁵¹ Countries that adopted the Dublin Declaration pledged to scale up programmes so that by 2010 at least 80% of those at highest risk of and most vulnerable to HIV and AIDS are covered by a wide range of prevention programmes providing access to information, services and prevention tools.⁵²

The Dublin Declaration stressed the need to identify and address factors that make these groups and communities particularly vulnerable to HIV and to promote and protect their health. In its position paper released the following year, *Intensifying HIV Prevention*, UNAIDS recommended not only specific services and tools that must be in place (see Box 1), but highlighted again the **necessity of legal analysis and the reform of legal frameworks** in order to remove legal barriers to effective and evidence-based interventions for HIV prevention, to overcome stigma and discrimination and to protect the rights of people living with HIV or at high risk of HIV infection.⁵³

Box 1: UNAIDS’ PRACTICAL GUIDELINES FOR INTENSIFYING HIV PREVENTION AMONG PEOPLE WHO INJECT DRUGS AND IN PRISONS⁵⁴

People who use drugs

In relation to people who use drugs, UNAIDS advises that the most effective and cost-effective HIV prevention programmes among people who use drugs are harm reduction measures, and that effective HIV prevention requires at least the following:

- Adequate coverage and low threshold access — including in correctional settings, to sterile injection equipment — to meet actual patterns of drug use.
- Access to quality, non-coercive drug treatment programmes especially drug substitution treatment such as methadone and buprenorphine.
- Removal of stigmatizing and coercive measures such as mandatory registration of PLHIV and forced HIV testing.
- Removal of legal barriers to access prevention and care, such as laws and policies that prevent the provision of sterile injecting equipment and/or access to drug substitution treatment such as methadone and buprenorphine and meaningful involvement of drug users at all levels of planning and policy and financial support for their organizations.

People in prison

In relation to people in prison, UNAIDS recommends, among other measures, the following:

- Removal of legal barriers and reform of prison procedures/rules to enable access to HIV prevention and care services by prisoners.
- Availability of condoms, sterile syringes and needles and skin-piercing equipment, and promotion of consistent and proper use of condoms.
- Access to drug treatment programmes, especially drug substitution treatment, with adequate protection of confidentiality.
- Access to HIV counselling and testing, antiretroviral and TB treatment and care and quality treatment of sexually transmitted infections.
- Review of drug control laws; provision of alternatives to imprisonment for minor drug-related offences; offer of treatment for drug users instead of imprisonment.

In 2009, the WHO, UNODC and UNAIDS issued a Technical Guide spelling out what is meant by comprehensive HIV prevention programmes for injecting drug users — namely nine essential interventions: (1) needle and syringe programmes; (2) opioid substitution therapy and other drug dependence treat-

51 Ibid., para. 10.

52 Ibid., para. 9.

53 UNAIDS, *Practical Guidelines for Intensifying HIV Prevention: Towards Universal Access* (Geneva: UNAIDS, 2005).

54 Ibid., p. 46 (Table 2.2) and p. 53 (Table 2.9).

ment; (3) HIV testing and counselling; (4) antiretroviral therapy; (5) prevention and treatment of sexually transmitted infections; (6) condom programmes for injecting drug users and their sexual partners; (7) targeted information, education and communication for injecting drug users and their sexual partners; (8) vaccination, diagnosis and treatment of viral hepatitis; and (9) prevention, diagnosis and treatment of tuberculosis.⁵⁵

On 27 July 2009, the UN Economic and Social Council (ECOSOC), a principal body to coordinate work in economic, social and related spheres, approved a resolution recognizing the need to:

- significantly expand and strengthen UNAIDS’ work with national governments and to work with all groups of civil society to address the gap in access to services for injecting drug users in all settings, including prisons;
- develop comprehensive models of appropriate service delivery for injecting drug users;
- tackle the issues of stigmatization and discrimination; and
- increase capacity and resources for the provision of a comprehensive package of services for injecting drug users, including harm reduction programmes in relation to HIV as elaborated in the Technical Guide.⁵⁶

A number of useful tools exist to assist with this task of legislative review and reform.⁵⁷ Complementing the *International Guidelines*, the Inter-Parliamentary Union, the UN Development Programme (UNDP) and UNAIDS have produced *Taking Action against HIV and AIDS: A Handbook for Parliamentarians*, providing detailed guidance to law-makers about factors to address and measures to include or avoid in a wide range of areas of law and policy relevant to HIV. The Handbook aims to ensure that national laws and policies are consistent with human rights obligations, and are informed by evidence and documented “good practice”.⁵⁸ The Handbook points out that over 25 years into the HIV epidemic, more than “half of the countries submitting reports to UNAIDS acknowledged the existence of policies that interfere with the accessibility and effectiveness of HIV-related measures for prevention and care,” and that this situation must change if countries are to meet the goal of universal access to HIV prevention, care, treatment and support (see Box 1).⁵⁹

Box 2: WHY ARE HUMAN RIGHTS IMPORTANT IN RESPONDING TO HIV?

“Human rights are relevant to the response to AIDS in at least three ways:

1. They decrease vulnerability to infection and to its impact. Certain groups, including people who inject drugs and prisoners, are more vulnerable to contracting HIV because they are unable to realise their civil, political, economic, social and cultural rights.
2. They decrease discrimination and stigma associated with HIV. Stigmatisation and discrimination of people living with HIV and AIDS may obstruct their access to treatment and may affect their rights to employment, housing and other rights. This, in turn, contributes to the vulnerability of others to infection, since HIV-related stigma and discrimination discourage individuals infected with, and affected by, HIV from contacting health and social services. The result is that those most needing information, education and counselling will not benefit even where such services are available.
3. They make national response more effective. Strategies to combat HIV epidemic are hampered where human rights are not respected. For example, discrimination against, and stigmatisation of, vulnerable groups such as people who inject drugs, sex workers, and men who have sex with men drives these communities underground. This inhibits the ability of social service organisations to reach those populations with prevention efforts, thereby increasing these groups’ vulnerability to HIV.”
— *Taking Action against HIV: Handbook for Parliamentarians* (2007)

55 WHO, UNODC, UNAIDS, *Technical Guide for Countries To Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users*, 2009.

56 Economic and Social Council, *Joint United Nations Programme on Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (UNAIDS)*, Resolution E/2009/L.23, 24 July 2009, para. 19.

57 As noted, the resource *Legislating for Health and Human Rights: Model Law on Drug Use and HIV/AIDS* (Canadian HIV/AIDS Legal Network, 2006), online at www.aidslaw.ca/modellaw, provides specific statutory provisions, based on evidence and international human rights law, to address HIV among people who use drugs, and was a key resource for the legislative review undertaken through this project. See Box 3 below.

58 Inter-Parliamentary Union, UNAIDS & UNDP, *Taking Action against HIV and AIDS: A Handbook for Parliamentarians*, No. 15/2007, online: <http://www.ipu.org/english/handbks.htm#aids07>.

59 Ibid., p. 70, quoting UNAIDS, *Report on the Global AIDS Epidemic 2006*.

Human rights violations negatively affect not only specific individuals, but also ultimately society as a whole. A number of key lessons have emerged from the response to HIV and AIDS to date, including the following:

- The protection of human rights is essential to safeguard human dignity in the context of HIV infection and to ensure an effective response. When human rights are not protected, people are more vulnerable to HIV infection. Where the human rights of people living with HIV (PLHIV) are not protected, such individuals are at greater risk of stigma and discrimination, and may become ill, unable to support themselves and their families; if not provided treatment, they may die.
- An effective response to AIDS requires the implementation of all human rights — civil and political, economic, social and cultural — in accordance with existing international human rights standards.
- Public health interests do not conflict with human rights. On the contrary, it has been recognised that, when human rights are protected, fewer people become infected and those living with HIV and their families can better cope with AIDS.
- A rights-based effective response to the HIV epidemic involves establishing appropriate government institutional responsibilities, implementing law reform and support services, and promoting supportive environment for groups vulnerable to HIV and those living with HIV.
- In the context of HIV infection, international human rights norms and pragmatic public health goals require States to adopt measures that may be perceived as controversial, particularly regarding the status of women and children, sex workers, people who inject drugs and men who have sex with men. It is, however, the responsibility of all States to identify how they can fully meet their human rights obligations and protect public health within their specific contexts.⁶⁰

Too often, laws and policies that are created to protect the rights and health of people living with HIV and AIDS, and of those at high risk of HIV infection, are not implemented in reality. In fact, among people who use drugs, the right to health and other human rights are often compromised by legislation, including provisions that limit or prohibit harm reduction interventions and treatment options or access to care and treatment for prisoners or people who use drugs who are HIV-positive.⁶¹

Almost everywhere in the world people who use illegal drugs are often among the most marginalised and stigmatised groups of society. They are among those who are more likely to end up in prison. They are vulnerable to a wide range of human rights violations such as abusive law enforcement practices, mass incarceration and denial of health services. “People who use drugs...are portrayed by media as morally suspect or socially dead... Portrayed as less than human, drug users are thus assumed to be undeserving of human rights. Indeed, some policymakers have recommended that they be treated like drugs: as things to be isolated, controlled and contained.”⁶²

Prisoners are at higher risk of HIV infection, because of sharing injecting equipment and unsafe tattooing practices, and unprotected sex. Despite efforts, often very expensive, at interdiction, drugs make their way into prisons in countries the world over, and drug use in prisons, including by injection, persists. Prisoners are also exposed to HIV through sex, both consensual and non-consensual. Furthermore, in countries where people who use drugs are subject to criminal prosecution, a high proportion of them — and hence a disproportionate number of people living with HIV — are likely to end up serving a prison sentence at some point. Yet just as an emphasis on prohibiting drug use and prosecuting and imprisoning people who use drugs contributes to high rates of incarceration, legislation often also hinders the implementation of effective HIV prevention measures in prisons. Furthermore, prisoners’ health care is often handled outside the regular health system. Theoretically, the same treatment protocols must be applied

60 Ibid., p. 32.

61 UNDP, *Reversing the Epidemic: HIV/AIDS in Eastern Europe and the Commonwealth of Independent States* (UNDP Regional Office for Eastern Europe and the CIS, 2004), p. 55 [hereinafter “Reversing the Epidemic”].

62 D. Barrett et al., *Recalibrating the Regime: The Need for a Human Rights-Based Approach to International Drug Policy* (London: The Beckley Foundation Drug Policy Programme, 2008).

in the penitentiary system as in the community, since it is the Ministry of Health that issues instructions and clinical protocols that are obligatory for treating certain health conditions or diseases nationwide. However, when prison medical services do not report to the Ministry of Health, the latter cannot check whether these instructions are strictly followed in prison.

As this report and the individual country reports in this publication illustrate, these observations are highly relevant to the context of the six countries of this project. As UNDP has noted, even though many countries of the region have successfully adopted human rights legislation, the gap between theory and practice remains significant, and full protection of human rights of marginalised groups at high risk of HIV transmission is not the reality. Furthermore, countries in the region continue to struggle with the legacy of the Soviet period, including poor involvement of civil society in informing public policy. Yet responses to the HIV epidemic will be most effective only if governments and communities are active in protecting the rights of the most vulnerable populations, those most at risk.⁶³

In much of the region, existing legislation is often mentioned by way of explanation for the lack of more effective and evidence-based approaches and services for addressing HIV among vulnerable groups. Yet the essence of the many of these laws hindering the introduction of such measures originates in a different era with a different social, political and epidemiological situation. National legislation is not set in stone and can be changed. It must serve the purpose of protecting the rights and interests of individuals and of society in general. When legislation stops serving its purpose, it is necessary to amend it. The HIV pandemic, globally and regionally, has thrown into stark relief the damage done to individuals, to public health and to society as a whole by marginalizing, discriminating against and criminalizing entire classes of people and thereby exacerbating their vulnerability to HIV; it highlighted the urgent necessity of respecting, protecting and fulfilling human rights in order to make the response to HIV more effective. This report aims to assist governments of the six participating countries (and others) in their work to eliminate barriers for access to HIV-related services for people who use drugs and prisoners. It identifies key legislative reforms and policies that countries can and should implement to harmonise their legislation and national programmes on HIV and drugs with the Millennium Development Goals, their pledges under the 2001 *Declaration of Commitments on HIV/AIDS* and the 2006 *Political Declaration on HIV/AIDS*, the *International Guidelines on HIV/AIDS and Human Rights* and other UN documents identifying best policies and practices in responding to HIV and AIDS. Legal reform and implementation of the recommendations presented here will assist in creating an enabling legal environment for achieving the goal of “universal access” to HIV prevention, care, treatment and support.

1.3 METHODOLOGY

With the overall objective of strengthening the response to HIV-infection in Central Asia and Azerbaijan, and the specific objective of facilitating universal access to HIV prevention, care, treatment and support for people who use drugs and prisoners, an assessment of national legislation and policy in the six project countries was conducted in 2007-08. The present report is an output of the UNODC Regional Project “Effective HIV prevention, treatment and care among vulnerable populations in countries of Central Asia and Azerbaijan” (2006-2010).

The ultimate goal of the legislation assessment was to develop recommendations for national legislation amendments (or the initiation of the development of new laws, regulations and implementing documents) related to the access of people who use drugs and people in prisons to HIV prevention, treatment and care in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan.

To fulfil the task UNODC Regional Office for Central Asia commissioned legal experts from the Canadian HIV/AIDS Legal Network, who served as UNODC consultants, and national experts from all countries participating in the project thus forming six national multi-disciplinary expert groups. The latter was a mix of technical experts nominated by governments/ministries, independent lawyers, and representatives of NGOs and affected communities. The UNODC Regional Project Coordinator guided and backstopped the whole process of the assessment, and national staff at UNODC Project Offices in all six countries served

63 *Reversing the Epidemic*, pp. 58-61.

as coordination focal points.

The work was done in accordance with the project's Terms of Reference, which described in detail the process of work, expected results, and the roles and responsibilities of consultants and UNODC staff.

Given the project's focus on the access to HIV-related services for people who use drugs and prisoners, the assessments and analyses examined the following legislative and normative documents:

- national programmes and strategies (and their operational plans) on HIV/AIDS and on drugs;
- criminal and administrative law;
- laws on drugs, health law, HIV/AIDS, the anti-discrimination and other relevant provisions of national laws;
- penal law;
- government regulations, guidelines and protocols in the above areas.

Special attention was given to the legislative provisions that should guarantee respect for, and the fulfilment and protection of, the human rights of people who use drugs and people in prison.

The task consisted of the following stages:

1. Assessment tool

An initial assessment tool was developed by the Canadian HIV/AIDS Legal Network for use by the national expert groups in analysing their respective countries' legislation and policy (and their application) that are of particular relevance to the response to HIV, particularly among people who use drugs and people in prison. The assessment tool was created on the basis of available guidance regarding best practices for HIV interventions and model practices for legal provisions to address HIV and drug use (see Box 3 below), taking into account characteristics of legal systems of the participating countries.⁶⁴ The assessment tool sought to assist national experts in identifying areas where aspects of national law raises human rights concerns and hinders effective HIV prevention and treatment among vulnerable populations, and in identifying potential reforms. (The assessment tool is reproduced in Appendix 2.)

2. Training of national expert groups

The national expert groups participated in a weeklong training session in Almaty, Kazakhstan in July 2007 delivered by two legal experts of the Canadian HIV/AIDS Legal Network and UNODC staff. The training focused on international human rights law and current developments in the area of HIV prevention and treatment for people who use drugs and prisoners, with special attention to techniques of legislation analysis and assessment. (The training module used in this session, which may be of use in other similar projects, is appended to this report as Appendix 3).

3. National assessments and reports

Using the assessment tool and materials provided, the national expert groups reviewed the relevant legislation and normative documents in their own countries. With multiple rounds of exchange of information, specifications and comments among the Legal Network, UNODC and the national expert groups, the latter prepared an extensive compilation of information as the product of the national assessments and drafted recommendations for legislative amendments. Based on information provided by the national expert groups and UNODC, and supplemented by additional research and drafting, the Canadian HIV/AIDS Legal Network elaborated the content and prepared a summary report for each country. Those reports include specific recommendations reflecting the current legislative and policy situation in each country. The six country reports are presented in Part II of this publication.

4. Integrated report

Drawing on the summary reports for each of the six countries, supplemented by additional information

⁶⁴ As requested by UNODC, this assessment tool was based in part on *Legislating for Health and Human Rights: Model Law on Drug use and HIV/AIDS* (Canadian HIV/AIDS Legal Network, 2006), online www.aidslaw.ca/modellaw.

provided by UNODC and further research and analysis, the Canadian HIV/AIDS Legal Network prepared the integrated report, constituting Part I of this publication. This integrated report situates the legislative review project in a regional context, analyses the common themes and key findings from the country assessments and highlights recommendations of broad relevance to the project countries and several recommendations to the international organizations working in the region

5. Check-list for self-assessment

Based on the questions and recommendations for reforms that had arisen in the course of the national assessments, the Canadian HIV/AIDS Legal Network, with input from and discussions with UNODC and the expert groups, prepared a 100-question check-list for countries to rate their progress toward reforming key aspects of national law, policy and practice affecting the response to HIV as it relates to vulnerable populations, particularly people who use drugs and people in prison. (The check-list is in Appendix 4.)

6. Presentation of project results

Draft country reports have been presented to, discussed with and commented upon by national stakeholders (parliamentarians, ministerial staff, NGOs representatives) in all six countries. In addition, results of the review and analysis of legislation, policy and practice in the six countries, and recommendations for reform, have been presented in various international and regional fora, and served as a basis for informing regional and country-level discussions with legislators and policy-makers for implementing selected reforms. Even before the release of this publication, the project has already stimulated legislative amendments in the region. This publication provides a basis for continued reforms to strengthen the participating countries' response to HIV as it relates to drug users and prison inmates, the two particularly vulnerable populations, and thereby contributes to achieving universal access to HIV prevention, care, treatment and support.

Box 3: *LEGISLATING FOR HEALTH AND HUMAN RIGHTS: MODEL LAW ON DRUG USE AND HIV/AIDS*

The model law is a resource prepared by the Canadian HIV/AIDS Legal Network in 2006 following extensive consultation with stakeholders around the world. It is a detailed framework of legal provisions and accompanying commentary addressing HIV prevention and treatment among people who inject drugs. It refers to examples of law from jurisdictions that have attempted to establish a clear legal framework for addressing HIV and AIDS issues among people who use drugs. This resource also incorporates human rights principles and obligations of states throughout the document.

The model law resource is designed to inform and assist policy-makers and advocates as they approach the task of reforming or making laws to meet the legal challenges posed by the HIV epidemic among people who use drugs. This resource can be most useful for those countries where injection drug use is a significant factor driving the HIV epidemic, and particularly for developing countries and countries in transition where legislative drafting resources may be scarce.

Legislating for Health and Human Rights consists of the following eight modules, each of which is a stand-alone document:

1. Criminal law issues
2. Treatment for drug dependence
3. Sterile syringe programmes
4. Supervised drug consumption facilities
5. Prisons
6. Outreach and information
7. Stigma and discrimination
8. Heroin prescription programmes.

The complete set of modules is available at www.aidslaw.ca/modellaw (in English) and www.aidslaw.ca/modellaw-ru (in Russian).

2. PROJECT COUNTRIES: AN OVERVIEW

As noted, this project identifies aspects of law and policy that are of particular relevance to addressing HIV infection among people who use drugs and prisoners. This chapter provides a summary overview of the regional context in which this project was undertaken: it introduces the extent of problematic drug use and of the HIV epidemic and related health concerns in the countries, and describes in general terms the political, legal, health care and criminal justice systems that must be engaged in making legislative and policy reforms to strengthen HIV prevention, care, treatment and support among vulnerable populations, and in particular people who use drugs and prisoners.

2.1 POPULATION AND GEOGRAPHY

The five Central Asian countries and the southern Caucasian country of Azerbaijan differ considerably in size, natural resources, political orientation and other indicators. Nevertheless, they share many characteristics in part as a result of their common history as former republics within the USSR. In addition, Azerbaijan shares common ethnic Turkic and Islamic religious roots with the Central Asian countries, as well as close historical contacts and energy and environmental connections through the Caspian Sea.⁶⁵

The total population of the Central Asian countries and Azerbaijan was approximately 70 million as of the middle of 2009.⁶⁶ Kazakhstan is the largest of the project countries by land mass, but with a population of only just over 15.8 million, has the lowest population density. It is also the wealthiest, accounting for just over half of the aggregate regional GDP, most of which derives from large petroleum reserves. Uzbekistan has the largest population (27.5 million), representing 45% of the entire population of the region. Kyrgyzstan and Turkmenistan have populations of similar size (5.3 million and 5.1 million respectively), but there are few other similarities between them: Turkmenistan is an arid country with vast energy reserves, especially of natural gas, while Kyrgyzstan is a small mountainous country with few natural resources other than water resources. Mountainous and landlocked, with a population of 7.4 million, Tajikistan is the smallest country by territory in Central Asia; aluminum production is a major industry and its many rivers hold potential for hydroelectric power as a commodity. Azerbaijan has the smallest land mass of the project countries and a population of 8.7 million.

2.2 DRUG USE

According to the UN, Central Asia as a region experienced a 17-fold rise in drug use from 1990 to 2002 (and especially of heroin injection), the highest growth rate in the world during that period.⁶⁷ The number of people undergoing drug dependence treatment in Tajikistan quadrupled over the period from 1996 to 2000; health care experts have suggested the real number of people who use drugs may be 10-15% higher.⁶⁸ In Turkmenistan, the number of people using drugs registered at narcological services increased approximately 8-fold between 1991 and 2001.⁶⁹ Between 1991 and 2001, in Kyrgyzstan, the number of people using drugs increased by 340%.⁷⁰ UNDP has reported that drug use has become increasingly dangerous, with poor quality heroin administered intravenously being the most commonly used.⁷¹ In addition, the average age of those using drugs has fallen, while the proportion of people with drug dependence who are women has increased (as has the number of women arrested for involvement in drug trafficking, which has quadrupled from 1993 to 1998).⁷²

65 UNDP, *Central Asia Human Development Report 2005*, p. 23.

66 Population Reference Bureau Data as of mid-2009; see www.prb.org.

67 UNDP, *Central Asia Human Development Report 2005*, p. 122.

68 Ibid.

69 Ibid. Historically, opium use administered orally or smoked was a quasi-acceptable behaviour in Turkmenistan. Since the 1970s, drug use patterns have been changing but even now Turkmenistan is different from other Central Asian countries in that smoking heroin (and to a lesser extent raw opium), rather than injecting, especially in rural area, remains a predominant mode of drug use. However, as observers note, this is probably not reflective of effective education about the risks of injection, such as HIV and other blood-borne diseases, but rather of the level of heroin and opium availability and affordability, which is the result of the complex interplay of socio-political, economic and cultural factors. For more discussion, see: N. Kerimi, "Opium Use in Turkmenistan: A Historical Perspective," *Addiction* 2000; 95(9): 1319-1333.

70 UNDP, *Central Asia Human Development Report 2005*, p. 122.

71 Ibid., p. 123.

72 Ibid.

A history of drug use is common among people imprisoned in the project countries, as is injection drug use in prisons. Some 60% of prisoners in Kyrgyzstan reported using drugs while incarcerated, with the majority injecting.⁷³ Sharing needles is a common practice: many prisoners reported lending, renting or selling their used needles to others for injecting.⁷⁴ Getting tattoos in prison is another common practice: among prisoners interviewed in three countries (Kyrgyzstan, Tajikistan and Uzbekistan), roughly 17% of the prison population in each country had received a tattoo while in prison, most of them with needles that had been used previously.⁷⁵ While prisoners have sex in prisons, a very small number of prisoners reported using condoms.⁷⁶

2.3 HIV EPIDEMIC

Until 1994, there had been few registered cases of HIV infection in the countries of the region.⁷⁷ However, HIV is now spreading in the region more rapidly than in many other parts of the world. While there were only 50 HIV cases in 1996, 8,078 cases had been registered by 2004,⁷⁸ and there was a 1600% increase in HIV prevalence between 2002 and 2004.⁷⁹ All six of the project countries are now experiencing HIV epidemics concentrated among people who inject drugs and their sexual partners, sex workers, and to a lesser degree, among men having sex with men.⁸⁰

The single largest driver of the epidemic in the region is unsafe injecting practices widespread among people who use drugs. An estimated 85% of HIV infections in Central Asia occur among injection drug users.⁸¹ According to data published by UNDP, levels of awareness of the risk of HIV infection through sharing needles and other items is limited among both people who use drugs and the population in general. More than 60% of those in Uzbekistan living with HIV are people who inject drugs. In several regions in Azerbaijan, Kazakhstan, Kyrgyzstan and Uzbekistan, an estimated 30-40% of injection drug users have contracted HIV.⁸²

At present, Uzbekistan shows the highest prevalence in Central Asia, with newly registered HIV cases rising exponentially from 28 cases in 1999 to 1,836 cases in 2003. Since then, the number of HIV cases newly registered each year has been rising more slowly; there were 2,205 people newly diagnosed as HIV-positive in 2006. Over the period from 2002 to 2006, the annual number of newly registered HIV cases among people who inject drugs more than doubled, from 631 to 1,464.⁸³ In Kazakhstan, the number of newly registered HIV cases increased from 699 in 2004 to 1,745 in 2006, and two-thirds (66%) of new HIV cases in 2006 were registered among people who inject drugs.⁸⁴ The HIV epidemics in Kyrgyzstan and Tajikistan are also primarily caused by injection drug use, but currently much smaller in scope than those in other countries in the region. Tajikistan shows an annual increase of newly diagnosed HIV cases from seven cases in 2000 to 41 cases in 2003 and 204 cases in 2006. In Kyrgyzstan, there were 16 cases in 2000, which figure rose to 132 cases in 2003 and 244 cases in 2006. Almost half (47%) of all HIV cases registered in Azerbaijan, where the epidemic is relatively new, were identified in 2005-2006.⁸⁵ In sharp contrast to the rest of the region, official reports claim only two HIV cases in Turkmenistan.⁸⁶

HIV prevalence in prisons is a major concern for countries in the region, with injection drug use and the prohibitive legal approach towards it — which results in many people who use drugs being imprisoned

73 UNODC & World Bank, *Regional Study on Drug Use and HIV/AIDS* (2007), p. 36.

74 Ibid., p. 52.

75 Ibid.

76 Ibid.

77 *Reversing the Epidemic*, p.11.

78 UNDP, *Central Asia Human Development Report 2005*, p. 146.

79 Ibid.

80 UNAIDS, *Eastern Europe and Central Asia: AIDS Epidemic Update Regional Summary* (2007).

81 UNDP, *Central Asia Human Development Report 2005*, p. 123.

82 Ibid.

83 UNAIDS, *Eastern Europe and Central Asia: AIDS Epidemic Update Regional Summary*, p. 6.

84 Ibid., p. 7.

85 Ibid., p. 9

86 Ibid, p. 8.

— as primary factors. In Tajikistan, HIV prevalence was reported at 6.2% among prisoners in institutions in Dushanbe and Khujand in 2005, and at 8.4% in 2006;⁸⁷ in 2005, there were 23 cases of HIV recorded in Tajik prisons, 95% of them among injection drug users.⁸⁸ In Kyrgyzstan, all 39 HIV cases recorded in 2005 among prisoners were among injection drug users; the reported cumulative number of HIV cases in Kyrgyzstan’s prisons is 277, almost 120 times the national average.⁸⁹ According to most recent figures from UNODC, estimated HIV prevalence among prisoners in Kyrgyzstan is 3.5% and the estimated prevalence of hepatitis C virus (HCV) is 40.3%.⁹⁰ In Azerbaijan in 2007, HIV diagnosed in 132 prisoners out of 5,663 tested (2.3%). According to UNODC, 72% of people living with HIV in Azerbaijan have a history of imprisonment.⁹¹

TABLE 1: Overview of drug use, prevalence of HIV infection and hepatitis C (HCV) in project countries⁹²

Country and population (millions)	Est. no. of IDUs	Est. no. of people with HIV	HIV prevalence among adults (age 15-49)	HIV prevalence among IDU	HCV prevalence among IDU	% of IDU among all HIV +	No of people on ARVs; and est. ARV coverage
Azerbaijan 8,500 ^a	21,189 people (374 women) registered as drug-dependent as of 2007 ^a 80,000 ^b	7,800 (range 4700-16000 as of 2008) ^g	0.2% (0.1-0.3%) ^g ; 23.9 per 100.000 popn. ^a	19-24% ^b	57% ^b	57.7% (2007) ^a	< 100; 6-24% (2007) ^h
Kazakhstan 15,532 ^c	186,000 ^b	12,000 range 7.000-29.000 ^g	0.1% (0.1-0.3%) ^g ; 54.0 per 100,000 ^h	3.9% ^b	65.7% ^b	72.7 ^g	< 500; 14-36% (2007) ^h
Kyrgyzstan 5,376 ^c	5,387 (registered) ^a 44.000 ^b	4,200 (1479 registered, 326 women, as of 2008) ^a	0.1% (0.1-0.3%) ^g ; 26.1 per 100,000 popn. ^a	1039 people (~ 7.4%) ^a 3-9% ^b	50.6% ^a	72% ^a	< 100; 8-26% (2007) ^h
Tajikistan 6,839 ^c	15,000 ^b 34,000 ^d (2007)	1153 ^a 10,000 (5,000-23,000) ^g	0.3% (0.1-0.6%); ^g 15.5 per 100,000. ^d	663 (57%) ^a 23.5% ^b	43.4% ^b	57.9% ^d 92007)	<100; 4-11% (2007) ^h
Turkmenistan 5,031 ^c	11,148 ^b	2 ^f ; < 1000 ^a	<0.1	n/a	n/a	n/a	0
Uzbekistan 27,769 ^c	80,000 ^a (15% women)	16,000 (8,100-45,000) ^g	0.1% (0.1 – 0.3%) ^g ; 11.7 per 100,000.	15.33% ^b	5% ^b	11.7% ^a 45% (2006) ^f	<500; 9-51% (2007) ^h

87 National progress report on the Declaration of Commitment on HIV/AIDS to the Special Session of the UN General Assembly: Tajikistan (2007), p. 9.

88 UNODC, *Regional Study on Drug Use and HIV/AIDS* (2007), p. 36.

89 Ibid., pp. 36, 40.

90 Official data provided by UNODC National Project Officers [on file].

91 Official data provided by UNODC National Project Officers [on file].

92 Table shows sources for data as follows: (In cases where sources showed significant discrepancy in numbers, two sources are presented.)

^a Official data provided by UNODC National Project Officers [on file].

^b C. Cook & N. Kanaef, *Global State of Harm Reduction 2008: Mapping the response to drug-related HIV and hepatitis C epidemics* (London: International Harm Reduction Program, 2008).

^c UNODC, *Compendium of Drug Related Statistics* (2008).

^d UNAIDS, Tajikistan, country progress report (January 2008); Uzbekistan country progress report (2008).

^e UNAIDS, *Eastern Europe and Central Asia: AIDS Epidemic Update Regional Summary* (2007).

^f Data submitted by national expert group of relevant country in preparing individual country reports.

^g UNAIDS country response pages, available via <http://www.unaids.org/en/CountryResponses/Countries/default.asp> (last accessed 22 June, 2009).

^h Country Epidemiological Fact Sheets on HIV and AIDS, 2008 update, available via <http://www.unaids.org/en/CountryResponses/Countries/default.asp> (last accessed 22 June, 2009).

2.4 GOVERNMENT AND GENERAL LEGAL SYSTEMS

Despite changes since achieving independence, the legal and government systems of states that were formerly part of the Soviet Union are still similar in many respects. Azerbaijan, Kazakhstan, Tajikistan and Uzbekistan are presidential republics with bicameral parliaments elected for a five-year period, while Kyrgyzstan and Turkmenistan have unicameral parliaments. Presidential power is strong in all six countries. In Kyrgyzstan, the president is elected by nationwide vote for a 5-year term, and, as a rule, with a limit of two consecutive terms. In Azerbaijan, Tajikistan and Turkmenistan, presidents are elected for five-year terms, with a limit of two terms in Azerbaijan and Tajikistan and no constitutional limit on terms in Turkmenistan. In Uzbekistan and Kazakhstan, the president is elected for 7 years and in Kazakhstan there is no limit for re-election.

Azerbaijan is the only one of the six project countries that is a member state of the Council of Europe and has hence signed and ratified the *European Convention on Human Rights*.⁹³ All six countries are member states of the Organization for Security and Cooperation in Europe (OSCE). All of them are member states of the UN and have ratified the main international conventions on human rights.⁹⁴ All of the project countries are member states of the Commonwealth of Independent States (CIS), the regional organisation composed of numerous former Soviet republics (although note that Turkmenistan reduced its status to being only an associate member in 2005, rather than remain a full member state). The countries have concluded a number of bilateral and multilateral agreements and treaties on cooperation to combat illegal drug trafficking.

All six of the project countries proclaim the primacy of international law, including ratified international treaties, over national legislation.⁹⁵ In each country international treaties automatically come into force upon ratification by a country’s Parliament;⁹⁶ the adoption of a new act introducing the treaty’s provisions into national legislation is not required. All legislation related to human rights and freedoms is subject to mandatory publication for access by the general public; otherwise, it is invalid. All the project countries have continental/civil legal systems, as opposed to common law systems, meaning there is little or no role for judicial precedents.

The Constitution of each of the project countries contains a broad range of human rights and freedoms. The legislative hierarchy consists of the Constitution at the apex, under which sit “codes” and “laws” (provisions that regulate distinct legal spheres), which are further supplemented by subsidiary instruments such as regulations, decrees, orders and instructions (e.g., by the President, by the Government as a whole, or by a minister).⁹⁷

National laws are often broad, declarative and contain norms to be spelled out in more detail via other (subordinate) legislation. Therefore, regulations and instructions made by the bodies of executive branch of government (e.g., presidential, cabinet or ministerial decrees, orders or regulations) may sometimes interpret the statutes adopted by the legislature in ways that limit human rights and freedoms.⁹⁸

Judicial power is exercised through civil, criminal and other proceedings (i.e. constitutional, administrative, economic). As a rule, a public defender is guaranteed for the accused person in the majority of criminal cases and court proceedings are public and open. There are courts at the levels of the city district, city, region (or equivalent), courts of appeal and supreme courts. Azerbaijan allows the existence of specialized

93 Azerbaijan joined the Council of Europe on 25 January 2001 and ratified the *European Convention* on 15 April 2002.

94 For a complete list of UN human rights treaties and the status of their ratification by various countries, see the website of the Office of the UN High Commissioner for Human Rights (www.ohchr.org).

95 E.g., *Constitution of the Azerbaijan Republic* (12 November 1995), Article 151.

96 E.g., *Constitution of Kazakhstan* (30 August 1995), Article 4.

97 E.g., see the *Law “On Regulatory and Legal Acts of the Republic of Uzbekistan,”* Law No. 160-II (14 December 2000), Article 14, or Kazakhstan’s *Law “On Regulatory and Legal Acts,”* Law No. 213-1 (24 March 1998).

98 For instance, the national law on HIV may state that discrimination against people living with HIV is prohibited, except for cases listed in special corresponding legislation. But a regulation — or often several regulations — then lists situations in which the rights of people living with HIV are or may be limited. Such limitations of rights may fail to take into account the epidemiological situation and the broader implications for public health, as well as the rights and freedoms of individuals. Moreover, legislation prohibits discrimination, while regulatory acts define and broaden it, thus contradicting country’s Constitution and international legal obligations. They may also contradict the rule in accordance with which limitation of rights is permissible only by statute and not by regulatory acts: e.g., *Constitution of Kazakhstan*, Article 39(1).

The national expert groups also consistently reported that the effectiveness of current drug dependence treatment is low. The majority of patients return to drug use almost immediately following the course of treatment, for which they often have to pay, despite the fact that according to the law it is supposed to be free.¹³¹

Prison conditions remain harsh and life-threatening: prisons are generally overcrowded and unsanitary, and disease, particularly the spread of tuberculosis, is a serious problem. For example, government officials in Tajikistan reported that 36 prisoners died of tuberculosis or AIDS-related diseases in 2007.¹³² According to the observations by the UN Committee Against Torture (CAT) on Tajikistan, there are numerous allegations concerning the widespread routine use of torture and ill-treatment by law enforcement and investigative personnel, particularly to extract confessions to be used in criminal proceedings.¹³³ There are reports of prisoners being denied or impeded in their access to legal counsel, family members and independent medical expertise. In Azerbaijan, Human Rights Watch has documented cases of torture, including through the use of electric shocks, severe beating, and threats of rape, as well as other incidents of torture in police stations throughout the country, as well as in prisons.¹³⁴ Corruption is widespread and prisoners must pay prison guards for privileges and sometimes even for health care.¹³⁵

3. ADMINISTRATIVE AND CRIMINAL LAW ISSUES

3.1 LAWS RELATED TO DRUGS: CURRENT SITUATION IN THE PROJECT COUNTRIES

In each of the six study countries, the law and its implementation reflect a repressive approach towards people who use drugs, and the national response to drugs accords a predominant role to law enforcement agencies, rather than health agencies. All six of the project countries have adopted similar national strategies and programmes against drug use and trafficking, with the dominant objectives of eliminating drug supply and use. However, in recent years the attitude has slowly begun to change: recent drug control programmes of some project countries (i.e. Kazakhstan and Kyrgyzstan) now include harm reduction measures.

Each country maintains administrative and criminal law prohibitions on drugs. Drug *use per se*, is formally prohibited in a number of countries, although it is not always penalized (e.g. with a penalty under the country’s administrative or criminal code). Legislation in Azerbaijan provides for administrative liability for drug use. In Tajikistan and Turkmenistan, drug use without a doctor’s prescription is prohibited according to the laws on drugs, but there is no penalty defined in administrative or criminal codes.¹³⁶ In Kazakhstan and Kyrgyzstan, drug use in public places leads to administrative penalty. Uzbekistan does not have either administrative or criminal liability for drug use, nor does the law on drugs state any prohibition on it.

Being intoxicated by narcotics or alcohol while committing an offence is an aggravating circumstance in the administrative and/or criminal laws of most of the project countries; this feature is inherited from the Soviet legal system. Azerbaijan and Tajikistan do not have such a provision, but it remains in the legislation of Turkmenistan, Uzbekistan, Kazakhstan and Kyrgyzstan.¹³⁷

Possession of insignificant quantities of a narcotic substance in all project countries entails administrative or criminal charges. Each country developed Schedules defining minimum and maximum amounts of narcotic drugs and psychotropic substances the possession of which leads to administrative or (more often) criminal punishment (see Appendix 1). In most of the project countries quantities of narcotic substances are divided into “small,” “large” and “extra large” quantities (or in the case of Uzbekistan, “small,” “exceeding small” and “large” quantities; in the case of Tajikistan, the four categories of “small”, “minor”, “large” and “extra large”).¹³⁸ The definitions of these different categories vary from country to country. The amounts for which possession leads to criminal liability are fairly small, with Uzbekistan and Kazakhstan having stricter limits and harsher penalties and Tajikistan taking a somewhat more liberal approach. Any quantity of heroin in Uzbekistan is classified as “exceeding small”; in Kazakhstan, any amount of heroin greater than 0.01 grams is defined as “large”; and in both countries possession of the above amounts of heroin leads to criminal liability. In Tajikistan, to illegally manufacture, produce, process, acquire, possess, transport or transfer narcotics in amounts less than “small” *without an intention to sell* is an administrative offence (e.g. less than 0.5g in the case of heroin) (see detailed description of amounts and penalties in individual country reports). Thus Uzbekistan and Kazakhstan’s approaches have been extremely restrictive, whereas some other countries in the region have recognized that penalizing possession of such limited quantities is unnecessary and counterproductive, leading to some reforms to increase the quantities considered to be small enough so as not to attract at least criminal liability. In 2004, Tajikistan amended its *Criminal Code* by increasing significantly the minimum quantity of substance that would be required to trigger criminal charges for possession,¹³⁹ and currently has the most liberal approach to defining such quantities in the region.¹⁴⁰ Similarly, in 2007, a decree adopted in Kyrgyzstan increased the minimum quantity of substances that attracts criminal liability.

131 M. Khidirov & M. An, in K. Malinowska-Sempruch, Sarah Gallagher (eds.), *War on Drugs, HIV/AIDS and Human Rights* (Russian edition) (IDEA, 2004), p. 190. (Note: This article exists only in the Russian edition of this book.)

132 U.S. Department of State (Bureau of Democracy, Human Rights, and Labour), Country Reports on Human Rights Practices 2007: Tajikistan (11 March 2008), online: www.state.gov/g/drl/rls/hrrpt/2007/100621.htm.

133 UN Committee Against Torture, *Tajikistan: Conclusions and recommendations of the Committee against Torture*, 37th Sess., 6-24 November 2006.

134 Human Rights Watch, Briefing Paper: Azerbaijan and the European Neighbourhood Policy (15 June 2005), online: <http://hrw.org/backgrounder/eca/azerbaijan0605>.

135 Ibid.

136 For example, in Tajikistan, neither the Criminal Code nor the Code on Administrative Responsibility makes it an offence merely to consume narcotic substances. However, Article 15 of the Law “On narcotic drugs, psychotropic substances, and precursors” states that consumption of narcotics and psychotropic substances without prescription is prohibited, although there is no penalty specified in law for breaching this section.

137 See individual country reports in Part II for specific references.

138 There is some variation in some countries’ schedules. The schedules of controlled substances, which determine the scope and harshness of criminal or administrative liability for various drug-related offences, do not necessarily reflect the pharmacological dangers of particular substances: see comparative tables of controlled substances in Appendix 1.

139 K. Malinowska-Sempruch & S. Gallagher (eds.), *War on Drugs, HIV/AIDS and Human Rights* (IDEA, 2004).

140 See Appendix 1.

nized in the Constitutions of both Uzbekistan and Turkmenistan, specifically the right to privacy, the right to freedom and personal inviolability and the right to protection from infringement of honour and dignity.¹⁸⁰ As recommended in the *International Guidelines on HIV/AIDS and Human Rights*, such provisions should be repealed by Uzbekistan and Turkmenistan.¹⁸¹

Recommendation 7: Reform criminal and administrative laws to decriminalize and depenalize sex workers

Laws that make it an administrative or criminal offence to engage in sex work do not prevent sex work, but they do lead to human rights abuses against sex workers and hinder HIV prevention and treatment efforts for this vulnerable population. Such laws drive sex workers underground or to marginal situations, making it harder for them to reach and be reached by health services as well as exposing them to a greater risk of violence, extortion and abuse by clients and by police. These laws need to be reformed so as to protect sex workers’ rights and their ability to protect their health and hence that of their clients. The *International Guidelines on HIV/AIDS and Human Rights* recommend that “criminal law should not impede provision of HIV prevention and care services to sex workers and their clients,” and that “adult sex work that involves no victimization” should be decriminalized.¹⁸²

Five of the project countries — Azerbaijan, Kazakhstan, Tajikistan, Turkmenistan and Uzbekistan — need to repeal administrative law provisions that penalize sex workers (as well as provisions imposing criminal liability for a repeated offence after an administrative penalty has been imposed). (Specific details of the applicable legislation, and specific recommendations, for each country are in the individual country reports in Part II.)

Kyrgyzstan is the only one of the six project countries in which there is no administrative liability for engaging in sex work. However, according to the assessment by the national expert group, sex workers in Kyrgyzstan are often harassed by police (prosecuted for offences of “debauchery” and “violation of public order”) and referred for compulsory STI testing. Therefore, in all countries, Kyrgyzstan included, health and law enforcement authorities should implement human rights training, including training in the area of human rights (including refraining from such involuntary HIV and other STIs testing). Human rights protecting bodies need to be trained to respond appropriately to abuses by law enforcement against sex workers.

Recommendation 8: Abolish HIV/STI-specific criminal offences and limit the scope of such laws

All six of the project countries specifically make it a crime to expose someone to HIV or transmit HIV, with *Criminal Code* provisions that are quite open-ended. Yet according to international policy recommendations, national legislation should not include criminal offences that single out HIV transmission or exposure; such an approach contributes to HIV-related stigma by singling out people living with HIV. Rather, crimes of general application should be used to handle these exceptional cases. The *International Guidelines on HIV/AIDS and Human Rights* recommend that any application of such general criminal offences “should ensure that the elements of foreseeability, intent, causality and consent are clearly and legally established to support a guilty verdict and/or harsher penalties.”¹⁸³ Furthermore, UNAIDS has recommended that the application of the criminal law should be limited to those cases where someone acts with malicious intent to transmit HIV and does in fact transmit the virus.¹⁸⁴

Many of the project countries also apply criminal liability even more broadly. In some project countries, there is criminal or administrative liability not only for HIV exposure and transmission, but also for exposure and transmission of other sexually transmitted infections (STIs). In Uzbekistan, it is also a crime to

180 Constitution of Turkmenistan, Articles 25 (privacy) and 43 (judicial protection of honour and dignity); Constitution of Uzbekistan, Articles 25 (right to freedom and personal inviolability) and 27 (protection of privacy honour and dignity).

181 *International Guidelines*, para. 21(b).

182 *Ibid.*, para. 21(c).

183 *Ibid.*, para. 21(a).

184 UNAIDS, *Policy Brief: Criminalization of HIV Transmission* (2008).

conceal the source of one’s HIV infection. In some countries (e.g., Kazakhstan), it is an administrative offence for someone to avoid medical examination for certain diseases, including HIV (in addition to criminal and administrative liability for avoiding drug testing).¹⁸⁵ In general, these sorts of provisions should be repealed or at least narrowed. Specific recommendations to this effect for each country are found in each of the relevant country reports (Part II).

185 *Code of Administrative Offences* of Kazakstan, Articles 326-327.

Tajikistan	According to national expert group, compulsory treatment for drug dependence is not enforced outside the correctional system.			
Turkmenistan Ministry of Health and Medical Industry	In 2009, 95 beds for treating elderly patients with drug dependence, which constitutes 7.4% of all narcological beds in the country (1290). Additionally, there are special treatment facilities for people with drug and alcohol dependence (treatment-labour camps) under the Ministry of Interior, where people are treated.	The term is 3-6 months, determined by court based on conclusions of the medical-narcological expertise.	197 people (1.7%) were treated involuntary in regular narcological facilities, out of all narcological patients (11,160), in 2007. In 2008, 1500 people were treated compulsorily in special facilities of the Ministry of Interior (in treatment-labour camps) .	Compulsory treatment is ordered by a court for people who violate public order, rights of others, or are a danger to security (including threat of violence), health and morale of population. The procedure includes a complaint by relatives or other party and necessary legal proceedings, including narcological expertise. Compulsory treatment could be inpatient and/or outpatient. Progress is reviewed every 6 months.
Uzbekistan Ministry of Health	In 2008, 704 beds for compulsory treatment, which is 41% of all narcological beds (1718).	The term is up to 18 months, determined by court based on conclusions of the medical-narcological expertise.	12.7% of all people who underwent drug dependence treatment were treated compulsorily in 2007; 13.3% in 2008.	Referral is done by law enforcement bodies on their own initiative, or following a request of relatives, work colleagues, or narcological facilities and necessary legal proceedings, including narcological expertise. Treatment is ordered by court to those who violate public order, rights of others, or are a threat to security (including threat of violence), health and morale of the population. There are no rules for review of progress. The term may be shortened depending on the progress.

Opioid substitution treatment (OST)

Despite the advent of HIV, the quick spread of the infection among injecting drug users since the early 1990s, the emerging problem of fatal drug overdose, and numerous other health and social problems associated with drug use, the issue of the low effectiveness of conventional drug dependence treatment has rarely been discussed even in professional circles in the project countries. Moreover, recommendations from WHO, UNODC and UNAIDS²²² to implement opioid substitution treatment (OST) as an effective method of treatment for dependence on opioids, and a powerful means for HIV prevention among injecting drug users, have been ignored or directly opposed by lead specialists of narcology (e.g., in Uzbekistan) and, anecdotally, drug control or law enforcement agencies in some other countries.

The three UN agencies define OST as the medically-supervised administration of a prescribed opioid medicine to people with a dependence on a pharmacologically related opioid, “for achieving defined treatment aims”.²²³ Since the opioid substitute, usually a medicine such as methadone or buprenorphine, is given as a liquid or tablet, OST can enable people with opioid dependence to stop injecting and avoid the harms of using contaminated injection equipment. Especially for this reason, these UN agencies emphasize that OST “should be considered as an important treatment option in communities with a high prevalence of opioid dependence,” and should be implemented as soon as possible in places where transmission of HIV through injection is significant.²²⁴

OST exists in one way or another in three of the project countries (Azerbaijan, Kyrgyzstan and recently established

222 WHO, UNODC and UNAIDS, *Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: WHO/UNODC/UNAIDS position paper* (Geneva, 2004).

223 Ibid., para. 20.

224 Ibid., introduction and para. 70.

pilot projects in Kazakhstan). Kyrgyzstan has been a regional pioneer in the introduction and scaling up of OST: by the end of 2009, there were just under 1000 patients in OST programmes at 18 sites run by health care facilities under the Ministry of Health and 3 sites in the penitentiary system under the Ministry of Justice.²²⁵ Until June 2009, a pilot OST project existed in Uzbekistan, at which time the government decided to discontinue it. This allegedly happened because of problems with the quality of services; however, efforts to address such concerns would have been a more productive response, rather than cancelling the project. OST remains unavailable in Tajikistan and Turkmenistan, both countries with thousands of people living with heroin dependence – although commitments to implement OST on a limited, pilot basis have been made in Tajikistan, with such programmes expected perhaps to start in 2010.

No legal obstacles for introducing and scaling up access to OST exist in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan and Turkmenistan.²²⁶ As the table below shows, the major pharmaceuticals used for OST, methadone and buprenorphine, are allowed for medicinal use, though under strict control, in all these countries. In Uzbekistan, methadone is classified as an illicit narcotic drug, but buprenorphine is allowed for use as a medicine.

Table 6: Legal status of methadone and buprenorphine²²⁷

METHADONE				
Country	Legal status	Whether on the national list of essential drugs	Legal provisions on import: national regulations	Comments
Azerbaijan	National Schedule II of Narcotic Drugs: allowed to be used for medical purposes but with limited importation and strict control measures for its circulation (<i>National Law on the Legal Circulation of Narcotics and Psychotropic Substances</i> , № 959-IIQ ,28 June 2005)	No.	Annually, quotas for procurement are defined by Ministry of Health and submitted to the Government, which issues decree allowing the procurement.	Procured by the state (Ministry of Health). The importation and use are based on provisions of the <i>National Law on the Legal Circulation of Narcotics and Psychotropic Substances</i> , № 959-IIQ 28 June 2005
Kazakhstan	National Schedule II: List of Narcotics and Psychotropic Substances that are Used for Medical Purposes under Strict Control (<i>Law On Narcotics, Psychotropic Substances, Precursors and Counteracting Measures to Prevent Illegal Circulation and Abuse of this Substances</i> , Law No 279, 10 July 1998)	No	Same rules for importation for methadone as for other narcotic drugs under strict control: Government Decree issued annually on quotas for narcotic drugs, psychotropic substances and other controlled substances (precursors); estimates made by Ministry of Health and cleared by Drug Control Agency/ Ministry of Interior.	Imported for the first time in 2008, Procurement supported by GFTAM.

225 Data presented by Dr R. Tokubayev, Director, Republican Centre of Narcology, at the 4th Central Asian Inter-Parliamentary Conference on HIV, 6-7 October 2009.

226 For example, Tajikistan's *Law “On narcological assistance”*, Article 9. This article mentions “alternative substitution therapy for those with narcotic addiction.”

227 Data as of 1 October 2009, as reported by UNODC National Project Officers.

Kyrgyzstan	National List No. 1: potentially dangerous narcotic drugs that can be used for medical purposes; allowed to be used for medical purposes but with limited importation and strict control measures for their circulation. (<i>Government of the Kyrgyz Republic, Decree On Narcotics, Psychotropic Substances and Precursors that are under Control in Kyrgyzstan, Decree No. 543, 9 November 2007</i>)	Yes	Government Decree on a one-time import of a limited amount of methadone issued annually.	Imported annually, procurement supported by GFATM.
Tajikistan	National List No. 2: Narcotic-contained plants and substances that are especially dangerous but could be used for medical purposes. Circulation limited and strict control measures applied. (<i>Government of the Republic of Tajikistan, Decree On Narcotics, Psychotropic Substances and Precursors, No. 390, 21 September 2000</i>)	No	No documents regulating import. In principle, to procure methadone the same regulations should be applied as for procurement of other narcotic drugs used in medicine (e.g., morphine)	Not imported.
Turkmenistan	List of Narcotics and Psychotropic Substances (used for medical purposes) with limited circulation and control measures. (<i>Presidential Decree "On approval of the lists of narcotics, psychotropic substances and precursors", No. 9192, 13 November 2007</i>).	No	No special provisions developed. In principle, to procure methadone the same regulations should be applied as for procurement of other narcotic drugs routinely used in medicine (e.g., morphine)	Not imported.
Uzbekistan	List of Narcotic Substances whose Circulation in the Republic of Uzbekistan is Prohibited (<i>List I Illicit Narcotics, Decree of the State Drug Control Commission of the Republic of Uzbekistan, No. 3, 22 May 1998</i>).	No	As a general rule methadone cannot be imported since it is prohibited for circulation in the country (List I).	Methadone was imported for the OST pilot project twice, in 2006 and 2007, with support of GFATM, Decree No. 7/3 of the State Commission on Drug Control (September 2003).

BUPRENORPHINE				
Country	Legal status	Whether on the national list of essential drugs	Legal provisions on import: national regulations	Comments /references
Azerbaijan	National List II of Psychotropic Substances: potentially dangerous psychotropic substances; allowed to be used for medical purposes but with strict control measures (<i>National Law on the Legal Circulation of Narcotics and Psychotropic Substances, № 959-IIQ, 28 June 2005</i>)	No	No special provisions.	Buprenorphine is not imported.
Kazakhstan	National Schedule II: List of Narcotics and Psychotropic Substances that are Used for Medical Purposes under Strict Control (<i>Law On Narcotics, Psychotropic Substances, Precursors and Counteracting Measures to Prevent Illegal Circulation and Abuse of this Substances No 279, 10 July, 1998</i>)	No	Same rules for importation as for methadone and other narcotic drugs under strict control.	Buprenorphine is not imported but is registered by the Ministry of Health.

Kyrgyzstan	National List III of Psychotropic Substances: potentially dangerous psychotropic substances; allowed to be used for medical purposes but with strict control measures for their circulation, except when they combined with other (non-controlled) substances. (<i>Government of the Kyrgyz Republic, Decree On Narcotics, Psychotropic Substances and Precursors that are under Control in Kyrgyzstan, Decree No. 543,9 November 2007</i>).	No	None. Theoretically can be imported in the same fashion as methadone and other narcotics under control.	Buprenorphine is not imported.
Tajikistan	National List No. 3: Substances with a certain level of risk of harms if used but that could be used for medical purposes. (<i>Government of the Republic of Tajikistan, Decree On Narcotics, Psychotropic Substances and Precursors, Decree No. 390, 21 September 2000</i>).	No	None. Theoretically can be imported more easily than methadone (as other psychotropic substance procured by the Ministry of Health).	Buprenorphine is not imported.
Turkmenistan	National List of Narcotics, Psychotropic Substances and Precursors (used as pharmaceuticals in medicine) with limited circulation and some control measures (<i>Presidential Decree "On approval of the lists of narcotics, psychotropic substances and precursors", No. 9192, 13 November 2007</i>).	No	None	Buprenorphine is not imported.
Uzbekistan	National List of Narcotic Substances with Limited Circulation in the Republic of Uzbekistan (List II, <i>Decree of the State Drug Control Commission of the Republic of Uzbekistan, No. 3, 22 May 1998</i>).	No	Imported based on annual request by Ministry of Health, cleared by Drug Control Agency, and the Government Decree issued for procurement of annual quota.	Imported twice (2006 and 2007) with financial support from GFATM.

The expert groups underlined that OST programmes are not regulated in the statutes of any of countries where they exist; mostly these programmes function on the basis of ministerial orders and instructions, which makes them more vulnerable to changes in political environment. Furthermore, access to these programmes is extremely limited because this treatment method is not institutionalized and still is run on a pilot basis with funding provided mostly by the Global Fund (except in Azerbaijan where the two OST sites are financed by the Ministry of Health but with very low coverage). Meanwhile, WHO, UNODC and UNAIDS produced a guide that could assist countries in setting the national targets for the access to OST which would make a positive impact on general health of the patients and contribute to the containment of HIV spread among general population.²²⁸

In addition, information from the country reports indicates that protocols used in these small-scale programmes could be improved to comply with best practices. For example, regulations should be drawn to prohibit reducing a patient's methadone dosage in order to punish a patient, as reportedly occurs in Azerbaijan. Similarly, provisions and protocols should be developed that would allow for people with stable results from the treatment to have the opportunity to take their methadone at home and not have to report to a narcological facility every day. On a positive note, the countries that do have some access to OST do not, at least on paper, limit the period during which a person can remain in treatment. However, the overall limited availability of these programmes is of great human rights and public health concern.

228 WHO/UNODC/UNAIDS, Technical Guide for countries to Set Targets for Universal Access to HIV prevention, treatment and care for injecting drug users (2009), online via <http://www.who.int/hiv/topics/idu/en/index.html>.

Table 5: Status of OST provision in the project countries (2009)²²⁹

Country	Date stated and location of first sites	No. of patients in first year	No. of sites as of Dec. 1, 2008	No. of patients as of Dec. 1, 2008	No. of sites by Oct. 1, 2009		Comments
					Location, no. of patients, and pharmaceutical used	Total no. of patients	
Azerbaijan	January 2004 National Narcology Centre in Baku.	60	1	100	2 sites (both in Baku): National Narcology Centre: 101 patients. National AIDS Centre: 15 patients. Methadone only.	116	OSTscale up is currently under consideration by Ministry of Health.
Kazakhstan	November 2008. Drug treatment clinics (dispensaries) in Temirtau and Pavlodar.	50	2	50 (25 at each site)	2 sites: drug dependence treatment clinics in Temirtau and Pavlodar (25 patients each). Methadone only.	50	There are plans in 2010 to increase the number of patients to a maximum of 100 per site.
Kyrgyzstan	2002 Two pilot sites in Bishkek and Osh city.	56 (Bishkek), 52 (Osh)	16 (including 1 site in Prison #47)	Total of 1569 patients since 2002. At the time of report: 829 patients outside prison, plus 97 patients receiving OST in Prison #47.	18 sites, located in narcological dispensaries in Bishkek and Osh, at the provincial AIDS centre in Osh and at Family Medicine Centres: ▪ 4 sites in Bishkek (260 patients) ▪ 7 sites in Chui oblast (335 patients) ▪ 5 sites in Osh city and Osh oblast (204 patients). 2 additional sites in pre-trial detention facility #21 (SIZO) and one site in Bishkek (55 patients). Methadone only.	926 (including about 100 in prisons)	Plans for expanding the access: new sites in SIZO #25 in Osh city and other prisons, and three community-based sites in Jalalabat, Uzgen and Kyzyl-kiya. .
Tajikistan	None	None	None	None	None	None	Plans of the Ministry of Health to start two OST (methadone) pilot sites in Dushanbe (120 patients) and Khujand (80 patients) by beginning of 2010
Turkmenistan	None	None	None	None	None	None	No definite plans for OST introduction
Uzbekistan	February 2006. Tashkent City Narcological Dispensary	125 (100 on buprenorphine, 25 on methadone)	1	142	1 site (Tashkent): 142 patients (57 on methadone and 85 on buprenorphine)	0	Was cancelled in June 2009.
Total in all 6 countries	n/a	n/a	20 sites	1060 patients	23 sites	1092 patients	

229 Data as of 1 October 2009, as reported by UNODC National Project Officers.

Management of overdose

People who are dependent on heroin (or other opioids) are at high risk of overdose, especially if they inject heroin of unknown toxicity or potency, or consume heroin concurrently with other substances. Overdose in turn carries a high risk of death. WHO, UNAIDS and UNODC estimate that, partly because of overdose, the mortality rate for people with heroin dependence is up to 20 times higher than that of non-heroin-dependent people of the same age.²³⁰ Death from overdose usually occurs within a few hours of administration of the dose in question.

It should be noted that ensuring access to opioid substitution therapy is one of the most effective ways to reduce deaths from overdose among people living with heroin dependence; another reason for its introduction and scale-up in the project countries.

In many countries, it is established practice to authorize emergency medical teams, hospital emergency rooms, and drug dependence treatment facilities to use the medicine naloxone to manage heroin overdose.²³¹ Naloxone is an opioid antagonist (i.e. it blocks opioid receptors in the nervous system), reducing the effects of heroin; it is quick-acting when administered by injection.²³² Naloxone is on WHO's Model List of Essential Medicines.²³³ Naloxone has been used for many years in many countries for prevention of overdose death without evidence of negative side effects or outcomes.²³⁴ Some experts have argued that friends and family members of heroin users or heroin users themselves should be allowed to carry naloxone for use in overdose emergencies they might witness, since many overdose deaths occur in the presence of friends or family before emergency health personnel arrive.²³⁵

In some of the project countries, naloxone may be used for overdose management. In the countries where naloxon is registered for medicinal use, it is used as a drug for an emergency intervention and must be prescribed by a physician. In Kazakhstan²³⁶ and Kyrgyzstan,²³⁷ naloxone is included in the national list of essential medicines, and is used as an antidote for poisoning and in emergency aid. In Tajikistan,²³⁸ naloxone is registered as a medicine, but it is also a controlled substance; this means that it could be used in medical facilities, but it cannot be handed out to people who use drugs and outreach workers for prevention of overdose. In Turkmenistan, naloxone is not registered and is not used for medical purposes. In Uzbekistan, until 2009 naloxone was not on the list of essential medicines, and therefore was not procured by the government (however, according to the experts, there were no limitations for its use). In 2009, the government of Uzbekistan made arrangements to procure naloxone, which is now available for overdose prevention and is distributed to health care facilities.²³⁹ In Azerbaijan, according to the expert group report, naloxone cannot be imported into the country officially, and it is not procured by the government.²⁴⁰ In none of the project countries where it is registered is naloxone currently available to outreach workers or to people who use drugs for purposes of using it in emergencies. The failure to take advantage of this life-saving treatment is a matter of urgent public health importance.

4.1.3 PREVENTION AND TREATMENT OF HIV INFECTION

National programmes on HIV and AIDS

National programmes on HIV/AIDS have been in place in the project countries for some time. However, at the outset, these plans and strategies rarely contained adequate, comprehensive HIV prevention provisions, and until recently did not touch upon populations considered at higher risk of infection. More often,

230 WHO, UNAIDS and UNODC, *Position paper*, para 4.

231 J. Strang et al., "Emergency naloxone for heroin overdose: Should it be available over the counter?" (editorial), *British Medical Journal* 2006; 333:614-615.

232 UNODC, "Reducing the harm of drug use and dependence (Treatment paper)" (Vienna: UNODC, 2007).

233 WHO, *Model List of Essential Medicines*, 15th ed. (Geneva: WHO, 2007), available via www.who.int.

234 Ibid.

235 Ibid.

236 The list is adopted by the Order of the Ministry of Health of the Republic of Kazakhstan, Order No. 883 (22 December 2004).

237 Government of the Kyrgyz Republic, "*On adopting a List of Essential medicines in the Kyrgyz Republic*", Resolution No. 759 (31.October 2006).

238 Ministry of Health, "On development of the narcological assistance in the Republic of Tajikistan," Order No. 485 (7 August 2006).

239 See country report of Uzbekistan in Part II.

240 See country report of Azerbaijan in Part II.

